The University of Chicago Header Logo

Mark J. Ratain

TitleProfessor
InstitutionUniversity of Chicago
DepartmentMedicine-Hematology and Oncology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Wesevich A, Ratain MJ. Accelerated Approval Program Versus NCCN Guidelines as Mechanisms for Early Drug Access. J Natl Compr Canc Netw. 2024 08; 22(6):435-436. PMID: 39151452.
      Citations:    Fields:    Translation:Humans
    2. Quintanilha JCF, Sibley AB, Liu Y, Niedzwiecki D, Halabi S, Rogers L, O'Neil B, Kindler H, Kelly W, Venook A, McLeod HL, Ratain MJ, Nixon AB, Innocenti F, Owzar K. Common variation in a long non-coding RNA gene modulates variation of circulating TGF-ß2 levels in metastatic colorectal cancer patients (Alliance). BMC Genomics. 2024 May 14; 25(1):473. PMID: 38745123; PMCID: PMC11092225.
      Citations:    Fields:    Translation:Humans
    3. Strohbehn GW, Ratain MJ. Sotorasib dosing and incremental cost ineffectiveness - implications and lessons for stakeholders. Nat Rev Clin Oncol. 2024 May; 21(5):331-332. PMID: 38291134.
      Citations:    Fields:    Translation:Humans
    4. Levit LA, Garrett-Mayer E, Peppercorn J, Ratain MJ. Critical importance of correctly defining and reporting secondary endpoints when assessing the ethics of research biopsies. Clin Trials. 2024 Apr 23; 17407745241244753. PMID: 38654414.
      Citations:    Fields:    
    5. Ratain MJ. Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer. Clin Pharmacol Ther. 2024 Sep; 116(3):508-510. PMID: 38605551.
      Citations:    Fields:    Translation:Humans
    6. Patel JN, Jiang C, Owzar K, Hertz DL, Wang J, Mulkey FA, Kelly WK, Halabi S, Furukawa Y, Lassiter C, Dorsey SG, Friedman PN, Small EJ, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Ratain MJ, Morris MJ, McLeod HL. Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance). Pharmacogenomics J. 2024 Mar 04; 24(2):6. PMID: 38438359; PMCID: PMC10912014.
      Citations:    Fields:    Translation:Humans
    7. Strohbehn GW, Ratain MJ. Special designations and the US Food and Drug Administration's "dual mandate". J Natl Cancer Inst. 2024 Feb 08; 116(2):177-179. PMID: 38062849.
      Citations:    Fields:    Translation:Humans
    8. Strohbehn GW, Stadler WM, Boonstra PS, Ratain MJ. Optimizing the doses of cancer drugs after usual dose finding. Clin Trials. 2024 Jun; 21(3):340-349. PMID: 38148731.
      Citations: 1     Fields:    Translation:Humans
    9. Lenz HJ, Pillonetto G, Mendez-Giraldez R, Yazdani A, Sanof H, Hadi R, Samiei E, Venook AP, Ratain MJ, Rashid N, Vincent BG, Qu X, Wen Y, Kosorok M, Symmans WF, Shen JPYC, Lee MS, Kopetz S, Nixon AB, Bertagnolli MM, Perou CM, Innocenti F, Yazdani A. Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy. Res Sq. 2023 Dec 15. PMID: 38168324; PMCID: PMC10760223.
      Citations:    
    10. Wesevich A, Peek ME, Ratain MJ. An Ethical and Financial Obligation for Sickle Cell Disease Gene Therapy in the United States. Ann Intern Med. 2024 01; 177(1):85-86. PMID: 38048579.
      Citations: 1     Fields:    Translation:Humans
    11. Quintanilha JCF, Sibley AB, Liu Y, Niedzwiecki D, Halabi S, Rogers L, O'Neil B, Kindler H, Kelly W, Venook A, McLeod HL, Ratain MJ, Nixon AB, Innocenti F, Owzar K. Common variation in a long non-coding RNA gene modulates variation of circulating TGF-ß2 levels in metastatic colorectal cancer patients (Alliance). medRxiv. 2023 Dec 04. PMID: 38106038; PMCID: PMC10723514.
      Citations:    
    12. Wesevich A, Ratain MJ. Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs? JAMA Oncol. 2023 11 01; 9(11):1489-1490. PMID: 37651126.
      Citations:    Fields:    Translation:Humans
    13. Wesevich A, Ratain MJ. Do patent applications and Cooperative Research and Development Agreements between the National Cancer Institute and industry serve the public interest? Nat Biotechnol. 2023 Nov; 41(11):1517-1519. PMID: 37950004.
      Citations:    Fields:    
    14. Ratain MJ, Strohbehn GW. Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues? Eur J Cancer. 2023 11; 194:113349. PMID: 37806256.
      Citations:    Fields:    Translation:Humans
    15. Wesevich A, Goldstein DA, Paydary K, Peer CJ, Figg WD, Ratain MJ. Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies. Br J Cancer. 2023 10; 129(9):1389-1396. PMID: 37542109; PMCID: PMC10628132.
      Citations: 4     Fields:    Translation:Humans
    16. Jacobson SI, Kacew AJ, Knoebel RW, Hsieh PH, Ratain MJ, Strohbehn GW. Alternative Trastuzumab Dosing Schedules Are Associated With Reductions in Health Care Greenhouse Gas Emissions. JCO Oncol Pract. 2023 09; 19(9):799-807. PMID: 37450776; PMCID: PMC10538895.
      Citations: 2     Fields:    Translation:Humans
    17. Tannock IF, Bouche G, Goldstein DA, Goto Y, Lichter AS, Prabhash K, Ranganathan P, Saltz LB, Sonke GS, Strohbehn GW, von Moos R, Ratain MJ. Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy. Ann Oncol. 2023 08; 34(8):638-644. PMID: 37230253.
      Citations: 1     Fields:    Translation:Humans
    18. Strohbehn GW, Lichter AS, Ratain MJ. US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action? J Clin Oncol. 2023 05 10; 41(14):2488-2492. PMID: 36780590.
      Citations: 5     Fields:    Translation:Humans
    19. Peer CJ, Schmidt KT, Arisa O, Richardson WJ, Paydary K, Goldstein DA, Gulley JL, Figg WD, Ratain MJ. In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation. J Clin Pharmacol. 2023 06; 63(6):672-680. PMID: 36624662; PMCID: PMC10175103.
      Citations: 4     Fields:    Translation:Humans
    20. Chen T, O'Donnell PH, Middlestadt M, Ruhnke GW, Danahey K, van Wijk XMR, Choksi A, Knoebel R, Hartman S, Yeo KJ, Friedman PN, Ratain MJ, Nutescu EA, O'Leary KJ, Perera MA, Meltzer DO. Implementation of pharmacogenomics into inpatient general medicine. Pharmacogenet Genomics. 2023 02 01; 33(2):19-23. PMID: 36729768.
      Citations: 4     Fields:    Translation:Humans
    21. Araujo D, Greystoke A, Bates S, Bayle A, Castelo-Branco L, de Bono J, Drilon A, Garralda E, Ivy P, Kholmanskikh O, Melero I, Pentheroudakis G, Petrie J, Plummer R, Ponce S, Postel-Vinay S, Siu L, Spreafico A, Stathis A, Steeghs N, Yap C, Yap TA, Ratain M, Seymour L, Calvo E. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022. Ann Oncol. 2023 01; 34(1):48-60. PMID: 36182023.
      Citations: 21     Fields:    Translation:Humans
    22. Ratain MJ, Tannock IF, Lichter AS. The dosing of ibrutinib and related Bruton's tyrosine kinase inhibitors: eliminating the use of brute force. Blood Adv. 2022 09 13; 6(17):5041-5044. PMID: 35816636; PMCID: PMC9631621.
      Citations:    Fields:    
    23. Levit LA, Kaneshiro J, Peppercorn J, Ratain MJ. An Expanded Role for IRBs in the Oversight of Research Biopsies. Ethics Hum Res. 2022 Sep; 44(5):32-41. PMID: 36047275.
      Citations:    Fields:    Translation:Humans
    24. Ratain MJ. Oncology Drug Prescribing: The Influences of Greed and Fear. JCO Oncol Pract. 2022 09; 18(9):e1384-e1387. PMID: 35834770.
      Citations: 2     Fields:    Translation:Humans
    25. Ratain MJ, Greenblatt DJ. Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware. J Clin Pharmacol. 2022 08; 62(8):925-927. PMID: 35412678; PMCID: PMC9541177.
      Citations: 2     Fields:    Translation:Humans
    26. LoRusso P, Ratain MJ, Doi T, Rasco DW, de Jonge MJA, Carneiro BA, Devriese LA, Petrich A, Modi D, Morgan-Lappe S, Nuthalapati S, Motwani M, Dunbar M, Glasgow J, Medeiros BC, Moreno V, Calvo E. Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study. Invest New Drugs. 2022 08; 40(4):762-772. PMID: 35467243; PMCID: PMC9035501.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    27. Strohbehn GW, Ratain MJ. Lorlatinib Exposed: A Far From Optimal Dose. Clin Pharmacol Ther. 2022 06; 111(6):1195-1196. PMID: 35394660.
      Citations:    Fields:    Translation:Humans
    28. Thomeas-McEwing V, Psotka MA, Gamazon ER, Friedman P, Konkashbaev A, Kubo M, Nakamura Y, Ratain MJ, Benza RL, Cox NJ, Gomberg-Maitland MI, Maitland ML. Two polymorphic gene loci associated with treprostinil dose in pulmonary arterial hypertension. Pharmacogenet Genomics. 2022 06 01; 32(4):144-151. PMID: 35383711.
      Citations: 1     Fields:    Translation:Humans
    29. Strohbehn GW, Cooperrider JH, Yang D, Fendrick AM, Ratain MJ, Zaric GS. Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance Plan. Value Health Reg Issues. 2022 Sep; 31:34-38. PMID: 35395499.
      Citations: 1     Fields:    Translation:Humans
    30. Papachristos A, Ratain MJ. Lurbinectedin-induced thrombocytopenia: the role of body surface area. Cancer Chemother Pharmacol. 2022 05; 89(5):573-575. PMID: 35362793; PMCID: PMC8972734.
      Citations:    Fields:    Translation:Humans
    31. Truong TM, Apfelbaum JL, Schierer E, Danahey K, Borden BA, Karrison T, Shahul S, Anitescu M, Gerlach R, Knoebel RW, Meltzer DO, Ratain MJ, O'Donnell PH. Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care. Pharmacogenet Genomics. 2022 04 01; 32(3):79-86. PMID: 34570085; PMCID: PMC8940738.
      Citations: 1     Fields:    Translation:Humans
    32. Hsieh PH, Kacew AJ, Dreyer M, Serritella AV, Knoebel RW, Strohbehn GW, Ratain MJ. Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings. NPJ Breast Cancer. 2022 Mar 14; 8(1):32. PMID: 35288585; PMCID: PMC8921207.
      Citations: 7     
    33. Truong TM, Apfelbaum JL, Danahey K, Schierer E, Ludwig J, George D, House L, Karrison T, Shahul S, Anitescu M, Choksi A, Hartman S, Knoebel RW, van Wijk XMR, Yeo KJ, Meltzer DO, Ratain MJ, O'Donnell PH. Pilot Findings of Pharmacogenomics in Perioperative Care: Initial Results From the First Phase of the ImPreSS Trial. Anesth Analg. 2022 11 01; 135(5):929-940. PMID: 35213469; PMCID: PMC9402808.
      Citations:    Fields:    Translation:Humans
    34. Reizine NM, Danahey K, Truong TM, George D, House LK, Karrison TG, van Wijk XMR, Yeo KJ, Ratain MJ, O'Donnell PH. Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing. Cancer. 2022 Apr 15; 128(8):1649-1657. PMID: 35090043; PMCID: PMC9153953.
      Citations: 2     Fields:    Translation:Humans
    35. Peer CJ, Heiss BL, Goldstein DA, Goodell JC, Figg WD, Ratain MJ. Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation. J Clin Pharmacol. 2022 04; 62(4):532-540. PMID: 34648187; PMCID: PMC9749861.
      Citations: 10     Fields:    Translation:Humans
    36. Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K, Schneider BP, Lin D, Innocenti F. Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022 Jan; 126(1):162. PMID: 34853435; PMCID: PMC8727676.
      Citations:    Fields:    
    37. Peer CJ, Zimmerman SM, Figg WD, Goldstein DA, Ratain MJ. Subcutaneous Atezolizumab: A Jab Without a Benefit. Clin Pharmacol Drug Dev. 2022 01; 11(1):134-135. PMID: 34951144.
      Citations: 1     Fields:    Translation:Humans
    38. Saulsberry L, Danahey K, Middlestadt M, O'Leary KJ, Nutescu EA, Chen T, Lee JC, Ruhnke GW, George D, House L, van Wijk XMR, Yeo KJ, Choksi A, Hartman SW, Knoebel RW, Friedman PN, Rasmussen LV, Ratain MJ, Perera MA, Meltzer DO, O'Donnell PH. Applicability of Pharmacogenomically Guided Medication Treatment during Hospitalization of At-Risk Minority Patients. J Pers Med. 2021 Dec 10; 11(12). PMID: 34945816; PMCID: PMC8709436.
      Citations: 1     
    39. Ratain MJ, Peer CJ, Figg WD, Goldstein DA. Dose Optimization of Pembrolizumab: Less May Be More. Clin Pharmacol Ther. 2022 05; 111(5):993. PMID: 34854077.
      Citations: 4     Fields:    Translation:Humans
    40. Strohbehn GW, Kacew AJ, Goldstein DA, Feldman RC, Ratain MJ. Combination therapy patents: a new front in evergreening. Nat Biotechnol. 2021 12; 39(12):1504-1510. PMID: 34880460.
      Citations: 3     Fields:    
    41. Patel JN, Jiang C, Owzar K, Mulkey F, Luzum JA, Mamon HJ, Haller DG, Dragovich T, Alberts SR, Bjarnason G, Willet CG, Niedzwiecki D, Enzinger P, Ratain MJ, Fuchs C, McLeod HL. Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). Pharmacogenet Genomics. 2021 12 01; 31(9):215-220. PMID: 34149004; PMCID: PMC8490297.
      Citations: 2     Fields:    Translation:Humans
    42. Tang NY, Pei X, George D, House L, Danahey K, Lipschultz E, Ratain MJ, O'Donnell PH, Yeo KJ, van Wijk XMR. Validation of a Large Custom-Designed Pharmacogenomics Panel on an Array Genotyping Platform. J Appl Lab Med. 2021 11 01; 6(6):1505-1516. PMID: 34263311; PMCID: PMC8561785.
      Citations: 4     Fields:    Translation:Humans
    43. Saulsberry L, Danahey K, Borden BA, Lipschultz E, Traore M, Ratain MJ, Meltzer DO, O'Donnell PH. Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics. NPJ Genom Med. 2021 Nov 01; 6(1):90. PMID: 34725343; PMCID: PMC8560901.
      Citations: 4     
    44. Ratain MJ. Designing Dose-Finding Phase I Clinical Trials: Top Questions That Should Be Discussed With Your Clinical Pharmacologist. JCO Precis Oncol. 2021 11; 5:935-936. PMID: 34994622.
      Citations:    Fields:    Translation:Humans
    45. Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K, Schneider BP, Lin D, Innocenti F. Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022 02; 126(2):265-274. PMID: 34616010; PMCID: PMC8770703.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    46. Quintanilha JCF, Wang J, Sibley AB, Xu W, Espin-Garcia O, Jiang C, Etheridge AS, Ratain MJ, Lenz HJ, Bertagnolli M, Kindler HL, Dickler MN, Venook A, Liu G, Owzar K, Lin D, Innocenti F. Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens. Int J Cancer. 2022 01 15; 150(2):279-289. PMID: 34528705; PMCID: PMC8627468.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    47. Ratain MJ, Tannock IF, Lichter AS. Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message? J Clin Oncol. 2021 11 01; 39(31):3423-3426. PMID: 34543056.
      Citations: 11     Fields:    Translation:Humans
    48. Reizine N, Danahey K, Schierer E, Liu P, Middlestadt M, Ludwig J, Truong TM, van Wijk XMR, Yeo KJ, Malec M, Ratain MJ, O'Donnell PH. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients. Oncologist. 2021 11; 26(11):e2042-e2052. PMID: 34423496; PMCID: PMC8571740.
      Citations: 7     Fields:    Translation:Humans
    49. Lipschultz E, Danahey K, Truong TM, Schierer E, Volchenboum SL, Ratain MJ, O'Donnell PH. Creation of a pharmacogenomics patient portal complementary to an existing institutional provider-facing clinical decision support system. JAMIA Open. 2021 Jul; 4(3):ooab067. PMID: 34458686; PMCID: PMC8390782.
      Citations: 2     
    50. Borden BA, Jhun EH, Danahey K, Schierer E, Apfelbaum JL, Anitescu M, Knoebel R, Shahul S, Truong TM, Ratain MJ, O'Donnell PH. Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application. Pharmacogenomics J. 2021 12; 21(6):691-711. PMID: 34376788; PMCID: PMC9267777.
      Citations: 1     Fields:    Translation:Humans
    51. Feldman RC, Hyman DA, Price WN, Ratain MJ. Negative innovation: when patents are bad for patients. Nat Biotechnol. 2021 08; 39(8):914-916. PMID: 34376839.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    52. Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, O'Donnell PH, Vokes EE, Kindler HL, Hseu R, Janisch LA, Dai J, Hoffman MD, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJ. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518. PMID: 34168049.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    53. Szmulewitz RZ, Stadler WM, Ratain MJ. The Abiraterone Dosing Chess Match With Johnson & Johnson-Back in Check. JAMA Oncol. 2021 06 01; 7(6):827-828. PMID: 33662094.
      Citations:    Fields:    Translation:Humans
    54. Ramirez J, House LK, Ratain MJ. Influence of N-acetyltransferase 2 gene polymorphisms on the in vitro metabolism of the epidermal growth factor receptor inhibitor rociletinib. Br J Clin Pharmacol. 2021 11; 87(11):4313-4322. PMID: 33818816.
      Citations:    Fields:    Translation:HumansCells
    55. Groenland SL, Ratain MJ, Chen LS, Gandhi V. The Right Dose: From Phase I to Clinical Practice. Am Soc Clin Oncol Educ Book. 2021 Mar; 41:92-106. PMID: 34010057.
      Citations: 4     Fields:    Translation:Humans
    56. Tannock IF, Ratain MJ, Goldstein DA, Lichter AS, Rosner GL, Saltz LB. Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. J Clin Oncol. 2021 03 20; 39(9):950-955. PMID: 33555940.
      Citations: 15     Fields:    Translation:Humans
    57. Ratain MJ, Moslehi JJ, Lichter AS. Ibrutinib's Cardiotoxicity-An Opportunity for Postmarketing Regulation. JAMA Oncol. 2021 02 01; 7(2):177-178. PMID: 33237281.
      Citations: 8     Fields:    Translation:Humans
    58. Reid P, Danahey K, Lopez Velazquez M, Ratain MJ, O'Donnell PH. Impact and applicability of pharmacogenomics in rheumatology: an integrated analysis. Clin Exp Rheumatol. 2021 Nov-Dec; 39(6):1385-1393. PMID: 33506753.
      Citations: 1     Fields:    Translation:Humans
    59. Polite BN, Ratain MJ, Lichter AS. Oncology's "Hockey Stick" Moment for the Cost of Cancer Drugs-The Climate Is About to Change. JAMA Oncol. 2021 01 01; 7(1):25-26. PMID: 33001134.
      Citations: 5     Fields:    Translation:Humans
    60. Reizine N, Vokes EE, Liu P, Truong TM, Nanda R, Fleming GF, Catenacci DVT, Pearson AT, Parsad S, Danahey K, van Wijk XMR, Yeo KJ, Ratain MJ, O'Donnell PH. Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial. Ther Adv Med Oncol. 2020; 12:1758835920974118. PMID: 33414846; PMCID: PMC7750903.
      Citations: 5     
    61. Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, Higgs EF, Bloodworth JC, Cabanov A, Wright RC, Koziol AK, Weiss A, Danahey K, Karrison TG, Edens CC, Bauer Ventura I, Pettit NN, Patel BK, Pisano J, Strek ME, Gajewski TF, Ratain MJ, Reid PD. COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 03; 109(3):688-696. PMID: 33210302; PMCID: PMC7753375.
      Citations: 31     Fields:    Translation:HumansCellsCTClinical Trials
    62. Truong TM, Lipschultz E, Schierer E, Danahey K, Ratain MJ, O'Donnell PH. Patient insights on features of an effective pharmacogenomics patient portal. Pharmacogenet Genomics. 2020 12; 30(9):191-200. PMID: 33017129; PMCID: PMC7539134.
      Citations: 5     Fields:    Translation:Humans
    63. Papachristos A, Ratain MJ. Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab. Clin Pharmacol Ther. 2021 07; 110(1):29-31. PMID: 33147355.
      Citations: 2     Fields:    Translation:Humans
    64. Goldstein DA, Ratain MJ, Saltz LB. Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19. JAMA Oncol. 2020 11 01; 6(11):1694-1695. PMID: 32459313.
      Citations: 13     Fields:    Translation:Humans
    65. Innocenti F, Sibley AB, Patil SA, Etheridge AS, Jiang C, Ou FS, Howell SD, Plummer SJ, Casey G, Bertagnolli MM, McLeod HL, Auman JT, Blanke CD, Furukawa Y, Venook AP, Kubo M, Lenz HJ, Parker JS, Ratain MJ, Owzar K. Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). Clin Cancer Res. 2021 01 01; 27(1):267-275. PMID: 32958699; PMCID: PMC7785628.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    66. Chua KC, Xiong C, Ho C, Mushiroda T, Jiang C, Mulkey F, Lai D, Schneider BP, Rashkin SR, Witte JS, Friedman PN, Ratain MJ, McLeod HL, Rugo HS, Shulman LN, Kubo M, Owzar K, Kroetz DL. Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy. Clin Pharmacol Ther. 2020 09; 108(3):625-634. PMID: 32562552; PMCID: PMC7718413.
      Citations: 15     Fields:    Translation:HumansCells
    67. Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, Higgs EF, Bloodworth JC, Cabanov A, Wright RC, Koziol A, Weiss A, Danahey K, Karrison TG, Edens CC, Ventura IB, Pettit NN, Patel B, Pisano J, Strek ME, Gajewski TF, Ratain MJ, Reid PD. COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19. medRxiv. 2020 Jul 26. PMID: 32743594; PMCID: PMC7386518.
      Citations: 1     
    68. Strohbehn GW, Reid PD, Ratain MJ. Applied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19. Clin Pharmacol Ther. 2020 09; 108(3):425-427. PMID: 32488861; PMCID: PMC7300962.
      Citations: 2     Fields:    Translation:Humans
    69. Ratain MJ, Lichter AS. Introduction by the Guest Editors. Cancer J. 2020 Jul/Aug; 26(4):279-280. PMID: 32732668.
      Citations:    Fields:    Translation:Humans
    70. Goldstein DA, Strohbehn GW, Serritella AV, Hyman DA, Lichter AS, Ratain MJ. Interventional Pharmacoeconomics. Cancer J. 2020 Jul-Aug; 26(4):330-334. PMID: 32732676.
      Citations: 4     Fields:    Translation:Humans
    71. Peer CJ, Goldstein DA, Goodell JC, Nguyen R, Figg WD, Ratain MJ. Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. Br J Clin Pharmacol. 2020 09; 86(9):1769-1777. PMID: 32424951; PMCID: PMC7444775.
      Citations: 13     Fields:    Translation:Humans
    72. Christian C, Borden BA, Danahey K, Yeo KJ, van Wijk XMR, Ratain MJ, O'Donnell PH. Pharmacogenomic-Based Decision Support to Predict Adherence to Medications. Clin Pharmacol Ther. 2020 08; 108(2):368-376. PMID: 32236960; PMCID: PMC7363565.
      Citations: 5     Fields:    Translation:Humans
    73. Goldstein DA, Ratain MJ. Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Letter. Clin Cancer Res. 2020 05 15; 26(10):2435. PMID: 32414762.
      Citations:    Fields:    Translation:Humans
    74. Serritella AV, Strohbehn GW, Goldstein DA, Lichter AS, Ratain MJ. Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value. Clin Pharmacol Ther. 2020 09; 108(3):487-493. PMID: 32298471.
      Citations: 12     Fields:    Translation:Humans
    75. O'Donnell PH, Trubetskoy V, Nurhussein-Patterson A, Hall JP, Nath A, Huo D, Fleming GF, Ingle JN, Abramson VG, Morrow PK, Storniolo AM, Forero A, Van Poznak C, Liu MC, Chang JC, Merkel DE, Peppercorn JM, Rugo HS, Dees EC, Hahn OM, Hoffman PC, Rosner GL, Huang RS, Ratain MJ, Cox N, Olopade OI, Wolff AC, Dolan ME, Nanda R, Translational Breast Cancer Research Consortium (TBCRC). Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633. PMID: 32378051.
      Citations: 6     Fields:    Translation:Humans
    76. Karas S, Etheridge AS, Tsakalozou E, Cecchin E, van Schaik RHN, Toffoli G, Ratain MJ, Mathijssen RHJ, Forrest A, Bies RR, Innocenti F, Ramírez J. Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients. AAPS J. 2020 03 17; 22(3):59. PMID: 32185579.
      Citations: 1     Fields:    Translation:Humans
    77. Etheridge AS, Gallins PJ, Jima D, Broadaway KA, Ratain MJ, Schuetz E, Schadt E, Molony C, Zhou Y, Mohlke KL, Wright FA, Innocenti F, Schroder A. A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased Phenotypes. Clin Pharmacol Ther. 2020 06; 107(6):1383-1393. PMID: 31868224; PMCID: PMC7816646.
      Citations: 12     Fields:    Translation:Humans
    78. Sharma MR, Mehrotra S, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Velasco M, Overmoyer B, Rugo HS, Ratain MJ, Gobburu JV. Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). J Clin Pharmacol. 2020 04; 60(4):444-452. PMID: 31802506; PMCID: PMC7064382.
      Citations: 5     Fields:    Translation:Humans
    79. Harvey RD, Ratain MJ. A Cost-Focused Alternative Cancer Medication Dispensing Strategy-"Pack Splitting". JAMA Oncol. 2019 12 01; 5(12):1691-1692. PMID: 31621807.
      Citations:    Fields:    Translation:Humans
    80. Strohbehn GW, Ratain MJ. Precision and Accuracy in the Brave New World of Basket Trials. JCO Precis Oncol. 2019 Dec; 3:1-5. PMID: 35100704.
      Citations:    Fields:    
    81. Goldstein DA, Ratain MJ. Alternative dosing regimens for atezolizumab: right dose, wrong frequency. Cancer Chemother Pharmacol. 2019 12; 84(6):1153-1155. PMID: 31630223.
      Citations: 13     Fields:    Translation:Humans
    82. Truong TM, Lipschultz E, Danahey K, Schierer E, Ratain MJ, O'Donnell PH. Assessment of Patient Knowledge and Perceptions of Pharmacogenomics Before and After Using a Mock Results Patient Web Portal. Clin Transl Sci. 2020 01; 13(1):78-87. PMID: 31490020; PMCID: PMC6951853.
      Citations: 9     Fields:    Translation:Humans
    83. Jones RL, Ratain MJ, O'Dwyer PJ, Siu LL, Jassem J, DeJonge M, Rudin C, Sawyer M, Khayat D, Awada A, de Vos-Geelen JMPGM, Evans TRJ, Obel J, Brockstein B, DeGreve J, Baurain JF, Maki R, D'Adamo D, Dickson M, Undevia S, Geary D, Janisch L, Bedard PL, Abdul Razak AR, Kristeleit R, Vitfell-Rasmussen J, Walters I, Kaye SB, Schwartz G, Medioni J. Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. Eur J Cancer. 2019 10; 120:132-139. PMID: 31522033; PMCID: PMC8852771.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    84. Hernandez W, Danahey K, Pei X, Yeo KJ, Leung E, Volchenboum SL, Ratain MJ, Meltzer DO, Stranger BE, Perera MA, O'Donnell PH. Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation. Pharmacogenomics J. 2020 02; 20(1):126-135. PMID: 31506565; PMCID: PMC7184888.
      Citations: 9     Fields:    Translation:Humans
    85. Truong TM, Apfelbaum J, Shahul S, Anitescu M, Danahey K, Knoebel RW, Liebovitz D, Karrison T, van Wijk XMR, Yeo KJ, Meltzer D, Ratain MJ, O'Donnell PH. The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care. Clin Pharmacol Ther. 2019 12; 106(6):1179-1183. PMID: 31433489; PMCID: PMC7214100.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    86. Ratain MJ, Goldstein DA, Lichter AS. Interventional Pharmacoeconomics-A New Discipline for a Cost-Constrained Environment. JAMA Oncol. 2019 Aug 01; 5(8):1097-1098. PMID: 31219513.
      Citations: 17     Fields:    
    87. Innocenti F, Jiang C, Sibley AB, Denning S, Etheridge AS, Watson D, Niedzwiecki D, Hatch AJ, Hurwitz HI, Nixon AB, Furukawa Y, Kubo M, Crona DJ, Kindler HL, McLeod HL, Ratain MJ, Owzar K. An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). Pharmacogenet Genomics. 2019 08; 29(6):123-131. PMID: 30889042; PMCID: PMC6636684.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    88. Levit LA, Peppercorn JM, Tam AL, Marron JM, Mathews DJH, Levit K, Roach N, Ratain MJ. Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement. J Clin Oncol. 2019 09 10; 37(26):2368-2377. PMID: 31343905.
      Citations: 15     Fields:    Translation:Humans
    89. Ratain MJ. Enhancing the Visibility and Prestige of Clinical Pharmacology as a Medical Subspecialty. Clin Pharmacol Ther. 2019 11; 106(5):914-915. PMID: 31298730.
      Citations:    Fields:    Translation:Humans
    90. Trendowski MR, El-Charif O, Ratain MJ, Monahan P, Mu Z, Wheeler HE, Dinh PC, Feldman DR, Ardeshir-Rouhani-Fard S, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Mushiroda T, Kubo M, Hannigan R, Strathmann F, Einhorn LH, Fossa SD, Travis LB, Dolan ME. Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. Clin Cancer Res. 2019 10 01; 25(19):5913-5924. PMID: 31296530; PMCID: PMC6774840.
      Citations: 9     Fields:    Translation:Humans
    91. House LK, Karrison TG, Janisch LA, Turcich M, Salgia R, Ratain MJ, Sharma MR, Ramírez J. Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. J Clin Pharmacol. 2019 12; 59(12):1632-1640. PMID: 31274208.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    92. Jhun EH, Ratain MJ, O'Donnell PH, Apfelbaum JL, Dickerson DM, Shahul S, Knoebel R, Danahey K. Pharmacogenomic considerations for medications in the perioperative setting. Pharmacogenomics. 2019 07; 20(11):813-827. PMID: 31411557; PMCID: PMC6949515.
      Citations: 3     Fields:    Translation:Humans
    93. Ratain MJ. The Role of Early-Phase Design-Letter. Clin Cancer Res. 2019 05 15; 25(10):3190. PMID: 31092614.
      Citations:    Fields:    
    94. Strohbehn GW, Ratain MJ. Immunotherapy and the A2A Adenosine Receptor: A Confounding Brew. Clin Pharmacol Ther. 2019 09; 106(3):498-500. PMID: 30951196.
      Citations:    Fields:    Translation:HumansCells
    95. Borden BA, Lee SM, Danahey K, Galecki P, Patrick-Miller L, Siegler M, Sorrentino MJ, Sacro Y, Davis AM, Rubin DT, Lipstreuer K, Polonsky TS, Nanda R, Harper WR, Koyner JL, Burnet DL, Stadler WM, Kavitt RT, Meltzer DO, Ratain MJ, O'Donnell PH. Patient-provider communications about pharmacogenomic results increase patient recall of medication changes. Pharmacogenomics J. 2019 12; 19(6):528-537. PMID: 30713337; PMCID: PMC6980369.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    96. Borden BA, Galecki P, Wellmann R, Danahey K, Lee SM, Patrick-Miller L, Sorrentino MJ, Nanda R, Koyner JL, Polonsky TS, Stadler WM, Mulcahy C, Kavitt RT, Ratain MJ, Meltzer DO, O'Donnell PH. Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study. Pharmacogenet Genomics. 2019 02; 29(2):31-38. PMID: 30531377.
      Citations: 13     Fields:    Translation:Humans
    97. Lee YM, Danahey K, Knoebel RW, Ratain MJ, Meltzer DO, O'Donnell PH. Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing. Pharmacogenet Genomics. 2019 02; 29(2):23-30. PMID: 30531378.
      Citations: 6     Fields:    Translation:Humans
    98. Thorn CF, Whirl-Carrillo M, Hachad H, McDonagh EM, Ratain MJ, Relling MV, Scott SA, Altman RB, Klein TE, Johnson JA. Essential Characteristics of Pharmacogenomics Study Publications. Clin Pharmacol Ther. 2019 01; 105(1):86-91. PMID: 30406943; PMCID: PMC6449845.
      Citations: 3     Fields:    Translation:Humans
    99. Ratain MJ. The Molecular Profiling Lottery: More Accuracy, Less Precision, and No Cost. Clin Cancer Res. 2019 02 15; 25(4):1136-1138. PMID: 30514776.
      Citations: 1     Fields:    Translation:Humans
    100. Innocenti F, Jiang C, Sibley AB, Etheridge AS, Hatch AJ, Denning S, Niedzwiecki D, Shterev ID, Lin J, Furukawa Y, Kubo M, Kindler HL, Auman JT, Venook AP, Hurwitz HI, McLeod HL, Ratain MJ, Gordan R, Nixon AB, Owzar K. Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep. 2018 11 05; 8(1):16332. PMID: 30397360; PMCID: PMC6218528.
      Citations: 8     Fields:    Translation:Humans
    101. Rashkin SR, Chua KC, Ho C, Mulkey F, Jiang C, Mushiroda T, Kubo M, Friedman PN, Rugo HS, McLeod HL, Ratain MJ, Castillos F, Naughton M, Overmoyer B, Toppmeyer D, Witte JS, Owzar K, Kroetz DL. A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance). Clin Pharmacol Ther. 2019 03; 105(3):738-745. PMID: 30260474; PMCID: PMC6379108.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    102. Shepshelovich D, Townsend AR, Espin-Garcia O, Latifovic L, O'Callaghan CJ, Jonker DJ, Tu D, Chen E, Morgen E, Price TJ, Shapiro J, Siu LL, Kubo M, Dobrovic A, Ratain MJ, Xu W, Mushiroda T, Liu G. Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. Cancer Med. 2018 11; 7(11):5478-5487. PMID: 30318772; PMCID: PMC6246957.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    103. Szmulewitz RZ, Stadler WM, Ratain MJ. Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al. J Clin Oncol. 2018 10 20; 36(30):3064-3065. PMID: 30188784.
      Citations:    Fields:    Translation:Humans
    104. Szmulewitz RZ, Karrison T, Stadler WM, Ratain MJ. Low-Dose Abiraterone With Food: Rebutting an Editorial. J Clin Oncol. 2018 10 20; 36(30):3060-3061. PMID: 30188785.
      Citations: 3     Fields:    Translation:Humans
    105. Ratain MJ, Goldstein DA. Time Is Money: Optimizing the Scheduling of Nivolumab. J Clin Oncol. 2018 Aug 27; JCO1800045. PMID: 30148658.
      Citations: 22     Fields:    
    106. Innocenti F, Owzar K, Jiang C, Etheridge AS, Sibley AB, Mulkey F, Niedzwiecki D, Glubb D, Neel N, Talamonti MS, Bentrem DJ, Seiser E, Yeh JJ, Van Loon K, McLeod H, Ratain MJ, Kindler HL, Venook AP, Nakamura Y, Kubo M, Petersen GM, Bamlet WR, McWilliams RR, Gordân R. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLoS One. 2018; 13(8):e0202272. PMID: 30107003; PMCID: PMC6091939.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    107. Hlubocky FJ, Sachs GA, Larson ER, Nimeiri HS, Cella D, Wroblewski KE, Ratain MJ, Peppercorn JM, Daugherty CK. Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials? J Clin Oncol. 2018 08 20; 36(24):2483-2491. PMID: 29985748; PMCID: PMC6097830.
      Citations: 6     Fields:    Translation:Humans
    108. Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317. PMID: 29948021; PMCID: PMC6739841.
      Citations: 9     Fields:    Translation:HumansCells
    109. Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook AP, Owzar K, Kroetz DL. Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res. 2018 10 01; 24(19):4734-4744. PMID: 29871907; PMCID: PMC6168379.
      Citations: 11     Fields:    Translation:HumansCells
    110. Wellmann R, Borden BA, Danahey K, Nanda R, Polite BN, Stadler WM, Ratain MJ, O'Donnell PH. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 2018 07 15; 124(14):3052-3065. PMID: 29742281; PMCID: PMC6354920.
      Citations: 7     Fields:    Translation:Humans
    111. Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018 05 10; 36(14):1389-1395. PMID: 29590007; PMCID: PMC5941614.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    112. Maitland ML, Piha-Paul S, Falchook G, Kurzrock R, Nguyen L, Janisch L, Karovic S, McKee M, Hoening E, Wong S, Munasinghe W, Palma J, Donawho C, Lian GK, Ansell P, Ratain MJ, Hong D. Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. Br J Cancer. 2018 04; 118(8):1042-1050. PMID: 29551775; PMCID: PMC5931107.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    113. VanderWeele DJ, Finney R, Katayama K, Gillard M, Paner G, Imoto S, Yamaguchi R, Wheeler D, Lack J, Cam M, Pontier A, Nguyen YTM, Maejima K, Sasaki-Oku A, Nakano K, Tanaka H, Vander Griend D, Kubo M, Ratain MJ, Miyano S, Nakagawa H. Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy. Eur Urol Focus. 2019 05; 5(3):416-424. PMID: 29398457; PMCID: PMC6586528.
      Citations: 10     Fields:    Translation:Humans
    114. Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618. PMID: 29437535; PMCID: PMC5978468.
      Citations: 264     Fields:    Translation:HumansCTClinical Trials
    115. Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018 05; 103(5):770-777. PMID: 29385237; PMCID: PMC5931215.
      Citations: 122     Fields:    Translation:Humans
    116. Ratain MJ, Chatelut E, Bruno R. Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors. Clin Pharmacol Ther. 2018 06; 103(6):956-958. PMID: 29194586.
      Citations: 7     Fields:    Translation:Humans
    117. House L, Seminerio MJ, Mirkov S, Ramirez J, Skor M, Sachleben JR, Isikbay M, Singhal H, Greene GL, Vander Griend D, Conzen SD, Ratain MJ. Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica. 2018 Oct; 48(10):973-983. PMID: 29050522; PMCID: PMC6129397.
      Citations: 2     Fields:    Translation:HumansCells
    118. Danahey K, Borden BA, Furner B, Yukman P, Hussain S, Saner D, Volchenboum SL, Ratain MJ, O'Donnell PH. Simplifying the use of pharmacogenomics in clinical practice: Building the genomic prescribing system. J Biomed Inform. 2017 Nov; 75:110-121. PMID: 28963061.
      Citations: 18     Fields:    Translation:Humans
    119. O'Donnell PH, Wadhwa N, Danahey K, Borden BA, Lee SM, Hall JP, Klammer C, Hussain S, Siegler M, Sorrentino MJ, Davis AM, Sacro YA, Nanda R, Polonsky TS, Koyner JL, Burnet DL, Lipstreuer K, Rubin DT, Mulcahy C, Strek ME, Harper W, Cifu AS, Polite B, Patrick-Miller L, Yeo KT, Leung E, Volchenboum SL, Altman RB, Olopade OI, Stadler WM, Meltzer DO, Ratain MJ. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869. PMID: 28398598; PMCID: PMC5636653.
      Citations: 32     Fields:    Translation:Humans
    120. Mehrotra S, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV. Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). AAPS J. 2017 09; 19(5):1411-1423. PMID: 28620884; PMCID: PMC5711539.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    121. Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF, Whirl-Carrillo M, Handelman SK, Palmer K, Pulley JM, Beller M, Schildcrout JS, Field JR, Weitzel KW, Cooper-DeHoff RM, Cavallari LH, O'Donnell PH, Altman RB, Pereira N, Ratain MJ, Roden DM, Embi PJ, Sadee W, Klein TE, Johnson JA, Relling MV, Wang L, Weinshilboum RM, Shuldiner AR, Freimuth RR, Pharmacogenomics Research Network Translational Pharmacogenetics Program. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems. Clin Pharmacol Ther. 2017 Sep; 102(3):502-510. PMID: 28090649; PMCID: PMC5511786.
      Citations: 71     Fields:    Translation:Humans
    122. Parsad S, Ratain MJ. Drug-Drug Interactions With Oral Antineoplastic Agents. JAMA Oncol. 2017 06 01; 3(6):736-738. PMID: 27737450.
      Citations: 5     Fields:    Translation:Humans
    123. Lee YM, McKillip RP, Borden BA, Klammer CE, Ratain MJ, O'Donnell PH. Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation. Pharmacogenet Genomics. 2017 05; 27(5):179-189. PMID: 28267054; PMCID: PMC5478379.
      Citations: 24     Fields:    Translation:Humans
    124. McKillip RP, Borden BA, Galecki P, Ham SA, Patrick-Miller L, Hall JP, Hussain S, Danahey K, Siegler M, Sorrentino MJ, Sacro Y, Davis AM, Rubin DT, Lipstreuer K, Polonsky TS, Nanda R, Harper WR, Koyner JL, Burnet DL, Stadler WM, Ratain MJ, Meltzer DO, O'Donnell PH. Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program. Clin Pharmacol Ther. 2017 07; 102(1):106-114. PMID: 27981566; PMCID: PMC5474215.
      Citations: 11     Fields:    Translation:Humans
    125. Resnik DB, Peppercorn J, Ratain MJ, Kimmelman J. Burdensome Research Procedures in Trials: Why Less Is More. J Natl Cancer Inst. 2017 04 01; 109(4). PMID: 28376159; PMCID: PMC5756064.
      Citations: 12     Fields:    Translation:Humans
    126. Parsad S, Ratain MJ. Food Effect Studies for Oncology Drug Products. Clin Pharmacol Ther. 2017 May; 101(5):606-612. PMID: 28073144.
      Citations: 6     Fields:    Translation:Humans
    127. Jimeno A, Sharma MR, Szyldergemajn S, Gore L, Geary D, Diamond JR, Fernandez Teruel C, Soto Matos-Pita A, Iglesias JL, Cullell-Young M, Ratain MJ. Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule. Invest New Drugs. 2017 08; 35(4):471-477. PMID: 28105566.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    128. Giacomini KM, Yee SW, Mushiroda T, Weinshilboum RM, Ratain MJ, Kubo M. Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. Nat Rev Drug Discov. 2017 Jan; 16(1):1. PMID: 27885282; PMCID: PMC5443656.
      Citations: 40     Fields:    Translation:Humans
    129. Li M, Seiser EL, Baldwin RM, Ramirez J, Ratain MJ, Innocenti F, Kroetz DL. ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J. 2018 01; 18(1):35-42. PMID: 27845419; PMCID: PMC5432414.
      Citations: 25     Fields:    Translation:Humans
    130. Goetz MP, Ratain M, Ingle JN. Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy. J Clin Oncol. 2016 11 10; 34(32):3944-3945. PMID: 27551126.
      Citations: 2     Fields:    Translation:Humans
    131. Sweis RF, Ratain MJ. Obviating the Need for Serial Biopsies Through Random Assignment. J Clin Oncol. 2017 01 10; 35(2):260. PMID: 28056195.
      Citations:    Fields:    Translation:Humans
    132. de Souza JA, Yap BJ, Wroblewski K, Blinder V, Hlubocky FJ, Nicholas LH, O'Connor JM, Brockstein B, Ratain MJ, Daugherty CK, Cella D, Araújo FS. Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 2017 02 01; 123(3):476-484. PMID: 27716900; PMCID: PMC5298039.
      Citations: 294     Fields:    Translation:Humans
    133. Yee SW, Momozawa Y, Kamatani Y, Tyndale RF, Weinshilboum RM, Ratain MJ, Giacomini KM, Kubo M. Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration. Clin Pharmacol Ther. 2016 Nov; 100(5):423-426. PMID: 27256705; PMCID: PMC5056156.
      Citations: 4     Fields:    Translation:Humans
    134. Nanda R, Stringer-Reasor EM, Saha P, Kocherginsky M, Gibson J, Libao B, Hoffman PC, Obeid E, Merkel DE, Khramtsova G, Skor M, Krausz T, Cohen RN, Ratain MJ, Fleming GF, Conzen SD. A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer. Springerplus. 2016; 5(1):947. PMID: 27386391; PMCID: PMC4929099.
      Citations: 18     
    135. Hussain S, Kenigsberg BB, Danahey K, Lee YM, Galecki PM, Ratain MJ, O'Donnell PH. Disease-drug database for pharmacogenomic-based prescribing. Clin Pharmacol Ther. 2016 08; 100(2):179-90. PMID: 26940584; PMCID: PMC5570547.
      Citations: 10     Fields:    Translation:Humans
    136. Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens SD, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 01; 22(19):4890-4900. PMID: 27143689; PMCID: PMC5050068.
      Citations: 33     Fields:    Translation:HumansAnimalsCTClinical Trials
    137. Sweis RF, Ratain MJ. Reply to T.A. Yap et al. J Clin Oncol. 2016 07 10; 34(20):2432-3. PMID: 27138578.
      Citations:    Fields:    Translation:Humans
    138. O'Donnell PH, Danahey K, Ratain MJ. The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone. Clin Pharmacol Ther. 2016 Apr; 99(4):401-4. PMID: 26756170; PMCID: PMC4830348.
      Citations: 7     Fields:    Translation:Humans
    139. Ratain MJ. Casting doubt on the scientific utility of post-treatment biopsies in phase 1 trials. Clin Adv Hematol Oncol. 2016 Feb; 14(2):78-9. PMID: 27057803.
      Citations:    Fields:    Translation:Humans
    140. Li CH, Bies RR, Wang Y, Sharma MR, Karovic S, Werk L, Edelman MJ, Miller AA, Vokes EE, Oto A, Ratain MJ, Schwartz LH, Maitland ML. Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling. Clin Transl Sci. 2016 Feb; 9(1):43-50. PMID: 26790562; PMCID: PMC4760886.
      Citations: 6     Fields:    Translation:Humans
    141. Sweis RF, Drazer MW, Ratain MJ. Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials. J Clin Oncol. 2016 Feb 01; 34(4):369-74. PMID: 26668350; PMCID: PMC4872035.
      Citations: 13     Fields:    Translation:Humans
    142. Rudek MA, Graham RA, Ratain MJ. Harmonization of Renal Function Assessment Is Needed During Early Clinical Development of Oncology Drugs. J Clin Oncol. 2016 Jan 10; 34(2):103-4. PMID: 26628472; PMCID: PMC5258115.
      Citations: 1     Fields:    Translation:Humans
    143. Seymour L, Groshen S, Rosner GL, Sullivan DM, Spriggs DR, Reeves S, Gravell A, Ivy SP, Ratain MJ. Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2015 Nov 15; 21(22):5057-63. PMID: 26567365; PMCID: PMC4646725.
      Citations: 1     Fields:    Translation:Humans
    144. Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, Lennox JL, Whirl-Carrillo M, Brummel SS, Ratain MJ, Klein TE, Schackman BR, Caudle KE, Haas DW, Clinical Pharmacogenetics Implementation Consortium, Guillemette C. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther. 2016 04; 99(4):363-9. PMID: 26417955; PMCID: PMC4785051.
      Citations: 88     Fields:    Translation:Humans
    145. Sharma MR, Ratain MJ. Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials. Clin Cancer Res. 2016 Feb 01; 22(3):527-9. PMID: 26467385; PMCID: PMC4738103.
      Citations: 1     Fields:    Translation:Humans
    146. O'Donnell PH, Karovic S, Karrison TG, Janisch L, Levine MR, Harris PJ, Polite BN, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9. PMID: 26199386; PMCID: PMC4677671.
      Citations: 1     Fields:    Translation:Humans
    147. Dressler LG, Deal AM, Owzar K, Watson D, Donahue K, Friedman PN, Ratain MJ, McLeod HL. Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). J Natl Cancer Inst. 2015 Oct; 107(10). PMID: 26160883; PMCID: PMC5758036.
      Citations: 5     Fields:    Translation:Humans
    148. House L, Ramirez J, Seminerio M, Mirkov S, Ratain MJ. In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7. Xenobiotica. 2015; 45(11):990-8. PMID: 26053558; PMCID: PMC4844176.
      Citations: 2     Fields:    Translation:Humans
    149. Kaufman AL, Spitz J, Jacobs M, Sorrentino M, Yuen S, Danahey K, Saner D, Klein TE, Altman RB, Ratain MJ, O'Donnell PH. Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. Mayo Clin Proc. 2015 Jun; 90(6):716-29. PMID: 26046407; PMCID: PMC4475352.
      Citations: 19     Fields:    Translation:Humans
    150. Ratain MJ, Geary D, Undevia SD, Coronado C, Alfaro V, Iglesias JL, Schilsky RL, Miguel-Lillo B. First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. Invest New Drugs. 2015 Aug; 33(4):901-10. PMID: 25947566.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    151. Crona DJ, Ramirez J, Qiao W, de Graan AJ, Ratain MJ, van Schaik RH, Mathijssen RH, Rosner GL, Innocenti F. Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Pharmacogenomics J. 2016 Feb; 16(1):54-9. PMID: 25869015; PMCID: PMC4729652.
      Citations: 10     Fields:    Translation:Humans
    152. Mirkov S, House LK, Ratain MJ, Ramírez J. Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10. Drug Metab Dispos. 2015 Jul; 43(7):928-35. PMID: 25870101; PMCID: PMC4468433.
      Citations: 4     Fields:    Translation:HumansCells
    153. de Souza JA, Yap B, Ratain MJ, Daugherty C. User beware: we need more science and less art when measuring financial toxicity in oncology. J Clin Oncol. 2015 Apr 20; 33(12):1414-5. PMID: 25732158.
      Citations: 7     Fields:    Translation:Humans
    154. Fleming GF, Schumm P, Friberg G, Ratain MJ, Njiaju UO, Schilsky RL. Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion. BMC Cancer. 2015 Feb 18; 15:69. PMID: 25885822; PMCID: PMC4336691.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    155. Moy B, Jagsi R, Gaynor RB, Ratain MJ. The impact of industry on oncology research and practice. Am Soc Clin Oncol Educ Book. 2015; 130-7. PMID: 25993151.
      Citations: 6     Fields:    Translation:Humans
    156. Odenike O, Halpern A, Godley LA, Madzo J, Karrison T, Green M, Fulton N, Mattison RJ, Yee KW, Bennett M, Koval G, Malnassy G, Larson RA, Ratain MJ, Stock W. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9. PMID: 25483416; PMCID: PMC4390421.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    157. Goetz MP, Sun JX, Suman VJ, Silva GO, Perou CM, Nakamura Y, Cox NJ, Stephens PJ, Miller VA, Ross JS, Chen D, Safgren SL, Kuffel MJ, Ames MM, Kalari KR, Gomez HL, Gonzalez-Angulo AM, Burgues O, Brauch HB, Ingle JN, Ratain MJ, Yelensky R. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. J Natl Cancer Inst. 2014 Dec 08; 107(2). PMID: 25490892; PMCID: PMC4565524.
      Citations: 16     Fields:    Translation:Humans
    158. Ratain MJ, Johnson JA. Meaningful use of pharmacogenetics. Clin Pharmacol Ther. 2014 Dec; 96(6):650-2. PMID: 25399712.
      Citations: 9     Fields:    Translation:Humans
    159. Patel JN, Jiang C, Hertz DL, Mulkey FA, Owzar K, Halabi S, Ratain MJ, Friedman PN, Small EJ, Carducci MA, Mahoney JF, Kelley MJ, Morris MJ, Kelly WK, McLeod HL. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer. 2015 Apr 01; 121(7):1025-31. PMID: 25417775; PMCID: PMC4368497.
      Citations: 14     Fields:    Translation:Humans
    160. Maitland ML, Xu CF, Cheng YC, Kistner-Griffin E, Ryan KA, Karrison TG, Das S, Torgerson D, Gamazon ER, Thomeas V, Levine MR, Wilson PA, Bing N, Liu Y, Cardon LR, Pandite LN, O'Connell JR, Cox NJ, Mitchell BD, Ratain MJ, Shuldiner AR. Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib. Clin Cancer Res. 2015 Jan 15; 21(2):365-72. PMID: 25411163; PMCID: PMC4323272.
      Citations: 15     Fields:    Translation:Humans
    161. Wang X, Owzar K, Gupta P, Larson RA, Mulkey F, Miller AA, Lewis LD, Hurd D, Vij R, Ratain MJ, Murry DJ, Alliance for Clinical Trials in Oncology. Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). Br J Clin Pharmacol. 2014 Nov; 78(5):1005-13. PMID: 24838014; PMCID: PMC4243874.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    162. Wassenaar CA, Conti DV, Das S, Chen P, Cook EH, Ratain MJ, Benowitz NL, Tyndale RF. UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):94-104. PMID: 25277794; PMCID: PMC4294984.
      Citations: 20     Fields:    Translation:Humans
    163. Wu K, Gamazon ER, Im HK, Geeleher P, White SR, Solway J, Clemmer GL, Weiss ST, Tantisira KG, Cox NJ, Ratain MJ, Huang RS. Genome-wide interrogation of longitudinal FEV1 in children with asthma. Am J Respir Crit Care Med. 2014 Sep 15; 190(6):619-27. PMID: 25221879; PMCID: PMC4214107.
      Citations: 8     Fields:    Translation:HumansCells
    164. Ratain MJ. Redefining the primary objective of phase I oncology trials. Nat Rev Clin Oncol. 2015 Mar; 12(3):126. PMID: 25200413.
      Citations: 2     Fields:    
    165. Beumer JH, Owzar K, Lewis LD, Jiang C, Holleran JL, Christner SM, Blum W, Devine S, Kolitz JE, Linker C, Vij R, Alyea EP, Larson RA, Ratain MJ, Egorin MJ. Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol. 2014 Nov; 74(5):927-38. PMID: 25163570; PMCID: PMC4210372.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    166. Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S, Reeves S, Ellis LM, Sargent DJ, Rosner GL, LeBlanc ML, Ratain MJ. Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2014 Aug 15; 20(16):4210-7. PMID: 25125258; PMCID: PMC4135521.
      Citations: 29     Fields:    Translation:Humans
    167. Ratain MJ. Targeted therapies: redefining the primary objective of phase I oncology trials. Nat Rev Clin Oncol. 2014 Sep; 11(9):503-4. PMID: 25091610.
      Citations: 15     Fields:    Translation:Humans
    168. Ratain MJ. Incorporating biomarkers into drug labeling. Clin Adv Hematol Oncol. 2014 Aug; 12(8):525-8. PMID: 25356576.
      Citations:    Fields:    Translation:Humans
    169. Fang H, Liu X, Choudhury N, Kubo M, Im HK, Konkashbaev A, Cox NJ, Ratain MJ, Nakamura Y, O'Donnell PH, Ramírez J. Establishment of CYP2D6 reference samples by multiple validated genotyping platforms. Pharmacogenomics J. 2014 Dec; 14(6):564-72. PMID: 24980783; PMCID: PMC4237721.
      Citations: 16     Fields:    Translation:HumansCells
    170. Innocenti F, Schilsky RL, Ramírez J, Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, Karrison T, Maitland ML, Salgia R, Ratain MJ. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014 Aug 01; 32(22):2328-34. PMID: 24958824; PMCID: PMC4105486.
      Citations: 70     Fields:    Translation:HumansCTClinical Trials
    171. de Souza JA, Yap BJ, Hlubocky FJ, Wroblewski K, Ratain MJ, Cella D, Daugherty CK. The development of a financial toxicity patient-reported outcome in cancer: The COST measure. Cancer. 2014 Oct 15; 120(20):3245-53. PMID: 24954526.
      Citations: 235     Fields:    Translation:Humans
    172. Ratain MJ. Forecasting unanticipated consequences of "The Sunshine Act": mostly cloudy. J Clin Oncol. 2014 Aug 01; 32(22):2293-5. PMID: 24934789; PMCID: PMC4876333.
      Citations: 8     Fields:    Translation:Humans
    173. Liu W, Gamazon ER, Mirkov S, Chen P, Wu K, Sun C, Cox NJ, Cook E, Das S, Ratain MJ, Ramírez J. Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver. Hum Mol Genet. 2014 Oct 15; 23(20):5558-69. PMID: 24879639; PMCID: PMC4168829.
      Citations: 30     Fields:    Translation:HumansCells
    174. Goetz MP, Brauch H, Ratain MJ, Cox NJ, Nakamura Y, Weinshilboum R, Ingle JN. Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst. 2014 Apr 03; 106(5). PMID: 24700804; PMCID: PMC4580553.
      Citations: 2     Fields:    Translation:Humans
    175. Szmulewitz RZ, Ratain MJ. Vemurafenib oral bioavailability: an insoluble problem. J Clin Pharmacol. 2014 Apr; 54(4):375-7. PMID: 24757719.
      Citations: 2     Fields:    Translation:Humans
    176. Bins S, Ratain MJ, Mathijssen RH. Conventional dosing of anticancer agents: precisely wrong or just inaccurate? Clin Pharmacol Ther. 2014 Apr; 95(4):361-4. PMID: 24646486.
      Citations: 11     Fields:    Translation:Humans
    177. Karovic S, Wen Y, Karrison TG, Bakris GL, Levine MR, House LK, Wu K, Thomeas V, Rudek MA, Wright JJ, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35. PMID: 24637941; PMCID: PMC4165641.
      Citations: 6     Fields:    Translation:Humans
    178. O'Donnell PH, Danahey K, Jacobs M, Wadhwa NR, Yuen S, Bush A, Sacro Y, Sorrentino MJ, Siegler M, Harper W, Warrick A, Das S, Saner D, Corless CL, Ratain MJ. Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project". Am J Med Genet C Semin Med Genet. 2014 Mar; 166C(1):68-75. PMID: 24616296; PMCID: PMC4000170.
      Citations: 58     Fields:    Translation:Humans
    179. Tabernero J, Geary D, Macarulla T, Kang SP, Kahatt C, Pita AS, Teruel CF, Siguero M, Cullell-Young M, Szyldergemajn S, Ratain MJ, Elez ME. First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors. Clin Cancer Res. 2014 Apr 15; 20(8):2205-14. PMID: 24563480.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    180. Chhibber A, Mefford J, Stahl EA, Pendergrass SA, Baldwin RM, Owzar K, Li M, Winer EP, Hudis CA, Zembutsu H, Kubo M, Nakamura Y, McLeod HL, Ratain MJ, Shulman LN, Ritchie MD, Plenge RM, Witte JS, Kroetz DL. Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). Pharmacogenomics J. 2014 Aug; 14(4):336-42. PMID: 24513692; PMCID: PMC4111770.
      Citations: 21     Fields:    Translation:HumansCellsCTClinical Trials
    181. Salgia R, Patel P, Bothos J, Yu W, Eppler S, Hegde P, Bai S, Kaur S, Nijem I, Catenacci DV, Peterson A, Ratain MJ, Polite B, Mehnert JM, Moss RA. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15; 20(6):1666-75. PMID: 24493831.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    182. Kim TW, Liu W, Myers JL, Mirkov S, Owzar K, Watson D, Mulkey F, Gamazon ER, Stock W, Undevia S, Innocenti F, Ratain MJ, Ramírez J. A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics. 2014 Feb; 24(2):129-32. PMID: 24300566; PMCID: PMC3901533.
      Citations: 2     Fields:    Translation:Humans
    183. Ratain MJ, Cox NJ, Henderson TO. Challenges in interpreting the evidence for genetic predictors of ototoxicity. Clin Pharmacol Ther. 2013 Dec; 94(6):631-5. PMID: 24241639.
      Citations: 10     Fields:    Translation:Humans
    184. Wang J, Carvajal-Carmona LG, Chu JH, Zauber AG, APC Trial Collaborators, Kubo M, Matsuda K, Dunlop M, Houlston RS, Sieber O, Lipton L, Gibbs P, Martin NG, Montgomery GW, Young J, Baird PN, Ratain MJ, Nakamura Y, Weiss ST, Tomlinson I, Bertagnolli MM. Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. Clin Cancer Res. 2013 Dec 01; 19(23):6430-7. PMID: 24084763; PMCID: PMC4037290.
      Citations: 7     Fields:    Translation:Humans
    185. Wu K, House L, Seminerio MJ, Ratain MJ, Ramírez J. Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs. Clin Cancer Res. 2013 Nov 01; 19(21):6039-43. PMID: 24056785; PMCID: PMC3832109.
      Citations: 3     Fields:    Translation:Humans
    186. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature. 2013 Sep 19; 501(7467):355-64. PMID: 24048068; PMCID: PMC5224525.
      Citations: 522     Fields:    Translation:Humans
    187. Seminerio MJ, Ratain MJ. Are drug labels static or dynamic? Clin Pharmacol Ther. 2013 Sep; 94(3):302-4. PMID: 23963217.
      Citations: 4     Fields:    Translation:Humans
    188. Dolan ME, Maitland ML, O'Donnell PH, Nakamura Y, Cox NJ, Ratain MJ. Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science. Pharmacogenomics. 2013 Sep; 14(12):1383-7. PMID: 24024891; PMCID: PMC4022693.
      Citations: 5     Fields:    Translation:Humans
    189. Bokelmann K, Jobst K, Ratain MJ, Tzvetkov MV, O'Brien VP, Ramírez J, Brockmöller J. Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene. J Pharmacol Exp Ther. 2013 Oct; 347(1):181-92. PMID: 23922447; PMCID: PMC3781413.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    190. Ratain MJ, Nakamura Y, Cox NJ. CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality. Clin Pharmacol Ther. 2013 Aug; 94(2):185-7. PMID: 23872831; PMCID: PMC3782290.
      Citations: 22     Fields:    Translation:Humans
    191. Ratain MJ, Seminerio MJ. Unmet needs in preventing adverse drug-drug interactions. Clin Adv Hematol Oncol. 2013 Aug; 11(8):520-1. PMID: 24518424.
      Citations:    Fields:    Translation:Humans
    192. Bhatta SS, Wroblewski KE, Agarwal KL, Sit L, Cohen EE, Seiwert TY, Karrison T, Bakris GL, Ratain MJ, Vokes EE, Maitland ML. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70. PMID: 23900000; PMCID: PMC3755935.
      Citations: 5     Fields:    Translation:HumansCells
    193. Innocenti F, Obel J, Xiong J, Mirkov S, Chiu YL, Katz DA, Carr RA, Zhang W, Das S, Adjei A, Moyer AM, Chen PX, Krivoshik A, Medina D, Gordon GB, Ratain MJ, Sahelijo L, Weinshilboum RM, Fleming GF, Bhathena A, Ramírez J. Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenet Genomics. 2013 Jul; 23(7):374-81. PMID: 23670235; PMCID: PMC3858967.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    194. Gamazon ER, Innocenti F, Wei R, Wang L, Zhang M, Mirkov S, Huang RS, Cox NJ, Ratain MJ, Liu W, Ramírez J. A genome-wide integrative study of microRNAs in human liver. BMC Genomics. 2013 Jun 13; 14:395. PMID: 23758991; PMCID: PMC3710218.
      Citations: 23     Fields:    Translation:Humans
    195. Kitano S, Myers J, Nakamura J, Yamane A, Yamashita M, Nakayama M, Tsukahara Y, Ushida H, Liu W, Ratain MJ, Amano M. A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection. PLoS One. 2013; 8(5):e62989. PMID: 23671647; PMCID: PMC3650034.
      Citations: 4     Fields:    Translation:Humans
    196. Maitland ML, Schwartz LH, Ratain MJ. Time to tumor growth: a model end point and new metric system for oncology clinical trials. J Clin Oncol. 2013 Jun 10; 31(17):2070-2. PMID: 23650409.
      Citations: 8     Fields:    Translation:Humans
    197. Sharma MR, Karrison TG, Kell B, Wu K, Turcich M, Geary D, Kang SP, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen EE. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67. PMID: 23553850; PMCID: PMC3674138.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    198. Seminerio MJ, Ratain MJ. Preventing adverse drug-drug interactions: a need for improved data and logistics. Mayo Clin Proc. 2013 Feb; 88(2):126-8. PMID: 23374616.
      Citations: 2     Fields:    Translation:Humans
    199. Wang LZ, Yeo W, Chan MY, Thuya WL, Lau JY, Wan SC, Wong AL, Zee YK, Lim R, Lee SC, Ho PC, Lee HS, Chan A, Ansher S, Ratain MJ, Goh BC, Ramírez J. Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One. 2013; 8(1):e54522. PMID: 23382909; PMCID: PMC3559838.
      Citations: 25     Fields:    Translation:HumansCellsCTClinical Trials
    200. Lewis LD, Miller AA, Owzar K, Bies RR, Markova S, Jiang C, Kroetz DL, Egorin MJ, McLeod HL, Ratain MJ, Alliance for Clinical Trials in Oncology. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics. 2013 Jan; 23(1):29-33. PMID: 23188068; PMCID: PMC3647228.
      Citations: 11     Fields:    Translation:Humans
    201. de Souza JA, Polite B, Perkins M, Meropol NJ, Ratain MJ, Newcomer LN, Alexander GC. Unsupported off-label chemotherapy in metastatic colon cancer. BMC Health Serv Res. 2012 Dec 29; 12:481. PMID: 23272659; PMCID: PMC3544564.
      Citations: 4     Fields:    Translation:Humans
    202. Maitland ML, Wu K, Sharma MR, Jin Y, Kang SP, Stadler WM, Karrison TG, Ratain MJ, Bies RR. Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther. 2013 Apr; 93(4):345-51. PMID: 23443753; PMCID: PMC3791430.
      Citations: 6     Fields:    
    203. Szmulewitz RZ, Ratain MJ. Playing Russian roulette with tyrosine kinase inhibitors. Clin Pharmacol Ther. 2013 Mar; 93(3):242-4. PMID: 23340477.
      Citations: 8     Fields:    Translation:Humans
    204. Wu K, Cohen EE, House LK, Zhang W, Ratain MJ, Bies RR, Ramírez J. Nonlinear population pharmacokinetics of sirolimus in patients with advanced cancer. CPT Pharmacometrics Syst Pharmacol. 2012 Dec 05; 1:e17. PMID: 23887441; PMCID: PMC3600722.
      Citations: 10     Fields:    
    205. Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL, Cancer and Leukemia Group B, Cox NJ, Dolan ME. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res. 2013 Jan 15; 19(2):491-9. PMID: 23204130; PMCID: PMC3549006.
      Citations: 35     Fields:    Translation:HumansCells
    206. Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ. Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet. 2013 Jan; 14(1):23-34. PMID: 23183705; PMCID: PMC3668552.
      Citations: 104     Fields:    Translation:HumansCells
    207. Sharma MR, Maitland ML, Ratain MJ. Models of excellence: improving oncology drug development. Clin Pharmacol Ther. 2012 Nov; 92(5):548-50. PMID: 23085878; PMCID: PMC3837384.
      Citations: 5     Fields:    Translation:Humans
    208. Giacomini KM, Yee SW, Ratain MJ, Weinshilboum RM, Kamatani N, Nakamura Y. Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med. 2012 Sep 26; 4(153):153ps18. PMID: 23019654; PMCID: PMC3963516.
      Citations: 27     Fields:    Translation:Humans
    209. Sharma MR, Maitland ML, Ratain MJ. RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point. Cancer Res. 2012 Oct 15; 72(20):5145-9; discussion 5150. PMID: 22952219.
      Citations: 44     Fields:    Translation:Humans
    210. Sharma MR, Maitland ML, Ratain MJ. Why RECIST works and why it should stay--reply to counterpoint. Cancer Res. 2012 Oct 15; 72(20):5158. PMID: 22952220.
      Citations: 3     Fields:    Translation:Humans
    211. O'Donnell PH, Bush A, Spitz J, Danahey K, Saner D, Das S, Cox NJ, Ratain MJ. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther. 2012 Oct; 92(4):446-9. PMID: 22929923; PMCID: PMC4482357.
      Citations: 85     Fields:    Translation:Humans
    212. Cohen EE, Wu K, Hartford C, Kocherginsky M, Eaton KN, Zha Y, Nallari A, Maitland ML, Fox-Kay K, Moshier K, House L, Ramirez J, Undevia SD, Fleming GF, Gajewski TF, Ratain MJ. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012 Sep 01; 18(17):4785-93. PMID: 22872575; PMCID: PMC4410974.
      Citations: 33     Fields:    Translation:HumansAnimalsCTClinical Trials
    213. Lewis LD, Ratain MJ. Might cigarettes be a "smoking gun" to reduce taxane myelotoxicity? Clin Cancer Res. 2012 Aug 15; 18(16):4219-21. PMID: 22859717; PMCID: PMC3440763.
      Citations: 1     Fields:    Translation:Humans
    214. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst. 2012 Aug 22; 104(16):1264; author reply 1266-8. PMID: 22851270.
      Citations: 30     Fields:    Translation:Humans
    215. Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res. 2012 Sep 15; 18(18):5099-109. PMID: 22843789; PMCID: PMC3445665.
      Citations: 99     Fields:    Translation:HumansCells
    216. Nguyen TD, Markova S, Liu W, Gow JM, Baldwin RM, Habashian M, Relling MV, Ratain MJ, Kroetz DL. Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression. Pharmacogenomics J. 2013 Oct; 13(5):396-402. PMID: 22664480; PMCID: PMC3435480.
      Citations: 17     Fields:    Translation:HumansCells
    217. Ratain MJ. Importance of food effects for oral oncology drugs. Clin Adv Hematol Oncol. 2012 Jun; 10(6):397-8. PMID: 22895243.
      Citations: 2     Fields:    Translation:Humans
    218. Sharma MR, Karrison TG, Jin Y, Bies RR, Maitland ML, Stadler WM, Ratain MJ. Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res. 2012 Apr 15; 18(8):2309-15. PMID: 22287601; PMCID: PMC3328614.
      Citations: 15     Fields:    Translation:Humans
    219. O'Donnell PH, Ratain MJ. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. Mol Oncol. 2012 Apr; 6(2):251-9. PMID: 22321460; PMCID: PMC5528362.
      Citations: 29     Fields:    Translation:HumansCells
    220. de Souza JA, Ratain MJ, Fendrick AM. Value-based insurance design: aligning incentives, benefits, and evidence in oncology. J Natl Compr Canc Netw. 2012 Jan; 10(1):18-23. PMID: 22223866.
      Citations: 10     Fields:    Translation:Humans
    221. Karrison TG, Ratain MJ, Stadler WM, Rosner GL. Estimation of Progression-Free Survival for All Treated Patients in the Randomized Discontinuation Trial Design. Am Stat. 2012; 66(3):155-162. PMID: 24039273; PMCID: PMC3769804.
      Citations: 2     
    222. Innocenti F, Owzar K, Cox NL, Evans P, Kubo M, Zembutsu H, Jiang C, Hollis D, Mushiroda T, Li L, Friedman P, Wang L, Glubb D, Hurwitz H, Giacomini KM, McLeod HL, Goldberg RM, Schilsky RL, Kindler HL, Nakamura Y, Ratain MJ. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res. 2012 Jan 15; 18(2):577-84. PMID: 22142827; PMCID: PMC3412624.
      Citations: 48     Fields:    Translation:Humans
    223. Feuerstein A, Ratain MJ. Oncology micro-cap stocks: caveat emptor! J Natl Cancer Inst. 2011 Oct 19; 103(20):1488-9. PMID: 21949082.
      Citations:    Fields:    Translation:Humans
    224. Ratain MJ. Flushing oral oncology drugs down the toilet. J Clin Oncol. 2011 Oct 20; 29(30):3958-9. PMID: 21931020.
      Citations: 8     Fields:    Translation:Humans
    225. Wu K, Janisch L, Karrison T, House LK, Innocenti F, Cohen EE, Ratain MJ, Ramírez J. The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1629-32. PMID: 21861128; PMCID: PMC3259680.
      Citations: 2     Fields:    Translation:Humans
    226. Humphrey RW, Brockway-Lunardi LM, Bonk DT, Dohoney KM, Doroshow JH, Meech SJ, Ratain MJ, Topalian SL, Pardoll DM. Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011 Aug 17; 103(16):1222-6. PMID: 21765011; PMCID: PMC4415086.
      Citations: 52     Fields:    Translation:HumansAnimals
    227. Sharma MR, Stadler WM, Ratain MJ. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011 Jul 20; 103(14):1093-100. PMID: 21709274; PMCID: PMC3139588.
      Citations: 32     Fields:    Translation:Humans
    228. Liu Y, Ratain MJ, Ramírez J. Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. Br J Clin Pharmacol. 2011 Jun; 71(6):917-20. PMID: 21235620; PMCID: PMC3099378.
      Citations: 18     Fields:    Translation:HumansCells
    229. Innocenti F, Cooper GM, Stanaway IB, Gamazon ER, Smith JD, Mirkov S, Ramirez J, Liu W, Lin YS, Moloney C, Aldred SF, Trinklein ND, Schuetz E, Nickerson DA, Thummel KE, Rieder MJ, Rettie AE, Ratain MJ, Cox NJ, Brown CD. Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet. 2011 May; 7(5):e1002078. PMID: 21637794; PMCID: PMC3102751.
      Citations: 144     Fields:    Translation:HumansCells
    230. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Ratain MJ, Salgia R, Müller T. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6. PMID: 21606412; PMCID: PMC3646303.
      Citations: 222     Fields:    Translation:HumansCTClinical Trials
    231. de Souza JA, Polite BN, Manning WG, Fendrick AM, Ratain MJ. Value-based insurance design in oncology. Lancet Oncol. 2011 Apr; 12(4):321-3. PMID: 21463832.
      Citations: 4     Fields:    Translation:Humans
    232. Gangadhar TC, Cohen EE, Wu K, Janisch L, Geary D, Kocherginsky M, House LK, Ramirez J, Undevia SD, Maitland ML, Fleming GF, Ratain MJ. Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res. 2011 Apr 01; 17(7):1956-63. PMID: 21447721; PMCID: PMC3077032.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    233. Cohen EE, Sharma MR, Janisch L, Llobrera M, House L, Wu K, Ramirez J, Fleming GF, Stadler WM, Ratain MJ. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9. PMID: 21439817; PMCID: PMC4116678.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    234. Ratain MJ. Current dilemmas in carboplatin dosing. Clin Adv Hematol Oncol. 2011 Mar; 9(3):237-8. PMID: 21475131.
      Citations:    Fields:    Translation:Humans
    235. Liu W, He L, Krishnaswamy S, Kanteti R, Wang YC, Salgia R, Ratain MJ, Ramírez J. Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res. 2011 Apr 01; 71(7):2423-7. PMID: 21292812; PMCID: PMC3070854.
      Citations: 22     Fields:    Translation:Humans
    236. Ratain MJ, Collins JM, Doroshow JH. Merrill Jon Egorin, MD, 1948-2010. Clin Pharmacol Ther. 2011 Feb; 89(2):163-5. PMID: 21252931.
      Citations:    Fields:    
    237. Kamdem LK, Liu Y, Stearns V, Kadlubar SA, Ramirez J, Jeter S, Shahverdi K, Ward BA, Ogburn E, Ratain MJ, Flockhart DA, Desta Z. In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec; 70(6):854-69. PMID: 21175441; PMCID: PMC3014069.
      Citations: 27     Fields:    Translation:HumansCells
    238. Altman RB, Kroemer HK, McCarty CA, Ratain MJ, Roden D. Pharmacogenomics: will the promise be fulfilled? Nat Rev Genet. 2011 01; 12(1):69-73. PMID: 21116304; PMCID: PMC3098748.
      Citations: 7     Fields:    Translation:Humans
    239. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ, Jänne PA. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703. PMID: 20979469; PMCID: PMC3014291.
      Citations: 1809     Fields:    Translation:HumansCTClinical Trials
    240. Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, Nelson SA, Weinshilboum RM, Ratain MJ, McLeod HL, Epstein RS, Ginsburg GS, Schilsky RL, Liu G, Flockhart DA, Ulrich CM, Davis RL, Lesko LJ, Zineh I, Randhawa G, Ambrosone CB, Relling MV, Rothman N, Xie H, Spitz MR, Ballard-Barbash R, Doroshow JH, Minasian LM. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705. PMID: 20944079; PMCID: PMC2982809.
      Citations: 20     Fields:    Translation:HumansAnimals
    241. Kang SP, Ramirez J, House L, Zhang W, Mirkov S, Liu W, Haverfield E, Ratain MJ. A pharmacogenetic study of vorinostat glucuronidation. Pharmacogenet Genomics. 2010 Oct; 20(10):638-41. PMID: 20729791; PMCID: PMC3636562.
      Citations: 15     Fields:    Translation:HumansCells
    242. O'Donnell PH, Undevia SD, Stadler WM, Karrison TM, Nicholas MK, Janisch L, Ratain MJ. A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs. 2012 Apr; 30(2):604-10. PMID: 20839028; PMCID: PMC3059335.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    243. Maitland ML, Hudoba C, Snider KL, Ratain MJ. Analysis of the yield of phase II combination therapy trials in medical oncology. Clin Cancer Res. 2010 Nov 01; 16(21):5296-302. PMID: 20837695; PMCID: PMC2970723.
      Citations: 23     Fields:    Translation:Humans
    244. Kang SP, Ratain MJ. Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. Clin Cancer Res. 2010 Sep 01; 16(17):4446-51. PMID: 20736327; PMCID: PMC2932769.
      Citations: 17     Fields:    Translation:Humans
    245. Hamberg P, Ratain MJ, Lesaffre E, Verweij J. Dose-escalation models for combination phase I trials in oncology. Eur J Cancer. 2010 Nov; 46(16):2870-8. PMID: 20691584.
      Citations: 21     Fields:    Translation:Humans
    246. Ratain MJ. Bar the windows but open the door to randomization. J Clin Oncol. 2010 Jul 01; 28(19):3104-6. PMID: 20516430.
      Citations: 3     Fields:    Translation:Humans
    247. Liu Y, House L, Ratain MJ, Ramírez J. The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation. Eur J Cancer. 2010 Jul; 46(11):2097-103. PMID: 20580994; PMCID: PMC2900545.
      Citations: 7     Fields:    Translation:HumansCells
    248. Maitland ML, Lou XJ, Ramirez J, Desai AA, Berlin DS, McLeod HL, Weichselbaum RR, Ratain MJ, Altman RB, Klein TE. Vascular endothelial growth factor pathway. Pharmacogenet Genomics. 2010 May; 20(5):346-9. PMID: 20124951; PMCID: PMC3086058.
      Citations: 10     Fields:    Translation:Humans
    249. Ratain MJ, Innocenti F, Ramírez J. Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol. 2010 Apr; 6(4):563-85. PMID: 20373870; PMCID: PMC3102300.
      Citations: 4     Fields:    Translation:Humans
    250. Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010 Mar 15; 16(6):1764-9. PMID: 20215557; PMCID: PMC2840069.
      Citations: 61     Fields:    Translation:Humans
    251. Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, Parchment R, Ratain MJ, Shankar LK, Stadler WM, True LD, Gravell A, Grever MR, Biomarkers Task Force of the NCI Investigational Drug Steering Committee. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010 Mar 15; 16(6):1745-55. PMID: 20215558.
      Citations: 103     Fields:    Translation:Humans
    252. Ratain MJ, Innocenti F. Individualizing dosing of irinotecan. Clin Cancer Res. 2010 Jan 15; 16(2):371-2. PMID: 20068075.
      Citations: 8     Fields:    Translation:Humans
    253. Liu Y, House L, Ratain MJ, Ramírez J. Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab Dispos. 2010 Jan; 38(1):32-9. PMID: 19850672; PMCID: PMC2802419.
      Citations: 29     Fields:    Translation:HumansCells
    254. Pacey S, Ratain MJ, Flaherty KT, Kaye SB, Cupit L, Rowinsky EK, Xia C, O'Dwyer PJ, Judson IR. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest New Drugs. 2011 Jun; 29(3):481-8. PMID: 20016927.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    255. Liu W, He L, Ratain MJ, Ramírez J. Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells. Clin Cancer Res. 2009 Dec 15; 15(24):7602-7607. PMID: 19996219; PMCID: PMC2794936.
      Citations: 12     Fields:    
    256. Gomberg-Maitland M, Maitland ML, Barst RJ, Sugeng L, Coslet S, Perrino TJ, Bond L, Lacouture ME, Archer SL, Ratain MJ. A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2010 Mar; 87(3):303-10. PMID: 20010555; PMCID: PMC3291104.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    257. Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, Undevia SD, Stadler WM, Elliott WJ, Ratain MJ. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009 Oct 01; 15(19):6250-7. PMID: 19773379; PMCID: PMC2756980.
      Citations: 68     Fields:    Translation:HumansCells
    258. Sharma MR, Maitland ML, Ratain MJ. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies. Cancer J. 2009 Sep-Oct; 15(5):426-30. PMID: 19826363.
      Citations: 4     Fields:    Translation:Humans
    259. Zhang W, Catenacci DV, Duan S, Ratain MJ. A survey of the population genetic variation in the human kinome. J Hum Genet. 2009 Aug; 54(8):488-92. PMID: 19644514; PMCID: PMC2776718.
      Citations: 1     Fields:    Translation:Humans
    260. Yang J, Bogni A, Schuetz EG, Ratain M, Dolan ME, McLeod H, Gong L, Thorn C, Relling MV, Klein TE, Altman RB. Etoposide pathway. Pharmacogenet Genomics. 2009 Jul; 19(7):552-3. PMID: 19512958; PMCID: PMC4164627.
      Citations: 21     Fields:    Translation:Humans
    261. Hoskins JM, Rosner GL, Ratain MJ, McLeod HL, Innocenti F. Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. Pharmacogenomics. 2009 Jul; 10(7):1139-46. PMID: 19604089; PMCID: PMC2748108.
      Citations: 6     Fields:    Translation:Humans
    262. Eichelbaum M, Altman RB, Ratain M, Klein TE. New feature: pathways and important genes from PharmGKB. Pharmacogenet Genomics. 2009 Jun; 19(6):403. PMID: 20161212; PMCID: PMC2715563.
      Citations: 10     Fields:    
    263. Yong WP, Kim TW, Undevia SD, Innocenti F, Ratain MJ. R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9. Eur J Cancer. 2009 Jul; 45(11):1904-8. PMID: 19464879; PMCID: PMC2758059.
      Citations:    Fields:    Translation:HumansCells
    264. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Relling M, Chen P, Das S, Rosner GL, Ratain MJ, Ramírez J. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009 Jun 01; 27(16):2604-14. PMID: 19349540; PMCID: PMC2690389.
      Citations: 108     Fields:    Translation:Humans
    265. Zhang W, He L, Liu W, Sun C, Ratain MJ. Exploring the relationship between polymorphic (TG/CA)n repeats in intron 1 regions and gene expression. Hum Genomics. 2009 Apr; 3(3):236-45. PMID: 19403458; PMCID: PMC2735212.
      Citations: 8     Fields:    Translation:HumansCells
    266. Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, Desai A, Hwang J, Villalona-Calero MA, Dees EC, Lewis LD, Fakih MG, Edelman MJ, Millard F, Frank RC, Hohl RJ, Ratain MJ. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009 Apr 10; 27(11):1800-5. PMID: 19255312; PMCID: PMC2668705.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    267. Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, Loewy JW, Kindler H, Stadler WM, Knowles HL, Bedrosian C, Ratain MJ. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15; 15(4):1428-34. PMID: 19228743; PMCID: PMC3147153.
      Citations: 34     Fields:    Translation:HumansCellsCTClinical Trials
    268. Glassman RH, Ratain MJ. Biomarkers in early cancer drug development: limited utility. Clin Pharmacol Ther. 2009 Feb; 85(2):134-5. PMID: 19151638.
      Citations: 7     Fields:    Translation:HumansAnimals
    269. Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009 Jan-Feb; 59(1):42-55. PMID: 19147868; PMCID: PMC3109906.
      Citations: 49     Fields:    Translation:Humans
    270. Ratain MJ, Sargent DJ. Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer. 2009 Jan; 45(2):275-80. PMID: 19059773.
      Citations: 46     Fields:    Translation:Humans
    271. Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, Stadler WM. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8. PMID: 18824708; PMCID: PMC2736992.
      Citations: 94     Fields:    Translation:Humans
    272. Perera MA, Thirumaran RK, Cox NJ, Hanauer S, Das S, Brimer-Cline C, Lamba V, Schuetz EG, Ratain MJ, Di Rienzo A. Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans. Pharmacogenomics J. 2009 Feb; 9(1):49-60. PMID: 18825162; PMCID: PMC2754748.
      Citations: 12     Fields:    Translation:HumansCells
    273. Zhang W, Liu W, Poradosu E, Ratain MJ. Genome-wide identification of genetic determinants for the cytotoxicity of perifosine. Hum Genomics. 2008 Sep; 3(1):53-70. PMID: 19129090; PMCID: PMC3525180.
      Citations: 5     Fields:    Translation:HumansCells
    274. Innocenti F, Mirkov S, Nagasubramanian R, Liu W, Bleibel WK, Shukla SJ, Hennessy K, Rosner GL, Cook E, Eileen Dolan M, Ratain MJ, Ramírez J. The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds. Cancer Chemother Pharmacol. 2009 Apr; 63(5):881-7. PMID: 18677484; PMCID: PMC2731557.
      Citations: 3     Fields:    Translation:HumansCells
    275. Conti RM, Meltzer DO, Ratain MJ. Nonprofit biomedical companies. Clin Pharmacol Ther. 2008 Aug; 84(2):194-7. PMID: 18679181; PMCID: PMC4591870.
      Citations: 4     Fields:    Translation:Humans
    276. Innocenti F, Liu W, Fackenthal D, Chen P, Ye X, Wu X, Zhang W, Mirkov S, Das S, Cook E, Ratain MJ, Ramírez J. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet Genomics. 2008 Aug; 18(8):683-97. PMID: 18622261; PMCID: PMC2680356.
      Citations: 39     Fields:    Translation:HumansCells
    277. Bartlett NL, Johnson JL, Wagner-Johnston N, Ratain MJ, Peterson BA, Cancer and Leukemia Group B. Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. Cancer Chemother Pharmacol. 2009 Apr; 63(5):793-8. PMID: 18648813; PMCID: PMC5802875.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    278. Undevia SD, Innocenti F, Ramirez J, House L, Desai AA, Skoog LA, Singh DA, Karrison T, Kindler HL, Ratain MJ. A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer. 2008 Aug; 44(12):1684-92. PMID: 18650079; PMCID: PMC2731567.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    279. Weiss ST, McLeod HL, Flockhart DA, Dolan ME, Benowitz NL, Johnson JA, Ratain MJ, Giacomini KM. Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov. 2008 07; 7(7):568-74. PMID: 18587383; PMCID: PMC2682785.
      Citations: 19     Fields:    Translation:Humans
    280. Perera MA, Innocenti F, Ratain MJ. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? Pharmacotherapy. 2008 Jun; 28(6):755-68. PMID: 18503403.
      Citations: 17     Fields:    Translation:Humans
    281. Bruce JY, Geary D, de Las Heras B, Soto A, Garcia Paramio P, Yovine A, Schilsky RL, Undevia SD, Ratain MJ. Phase I study of PM02734: Association of dose-limiting hepatotoxicity with plasma concentrations. J Clin Oncol. 2008 May 20; 26(15_suppl):2513. PMID: 27947731.
      Citations:    
    282. Gangadhar T, Cohen EE, Janisch L, House LK, Undevia SD, Fleming GF, Maitland ML, Ramirez J, Ratain MJ. A drug interaction study of sorafenib (S) and rapamycin (R) in patients with advanced malignancies. J Clin Oncol. 2008 May 20; 26(15_suppl):2545. PMID: 27947936.
      Citations:    
    283. Hlubocky FJ, Larson E, Sachs G, Lesniak MS, Ratain MJ, Daugherty CK. A study of informed consent (IC), age, and cognitive performance (CP) among advanced cancer patients (acp) in phase I trials. J Clin Oncol. 2008 May 20; 26(15_suppl):9523. PMID: 27948232.
      Citations:    
    284. Odenike O, Green M, Larson RA, Rich ES, Ott J, Ratain MJ, Stock W. Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms. J Clin Oncol. 2008 May 20; 26(15_suppl):7057. PMID: 27949624.
      Citations:    
    285. Ratain MJ, Benedetti FM, Janisch L, Khor S, Schilsky RL, Cohen EE, Maitland ML, Elias L, LoRusso PM. A phase I trial of GRN163L (GRN), a first-in-class telomerase inhibitor, in advanced solid tumors. J Clin Oncol. 2008 May 20; 26(15_suppl):3581. PMID: 27949674.
      Citations:    
    286. Hartford CM, Cohen EE, Fox-Kay K, Ott J, Jiang X, Kocherginsky M, Ratain MJ. Addition of grapefruit juice (GJ) to increase the bioavailability of high-dose weekly rapamcyin (R). J Clin Oncol. 2008 May 20; 26(15_suppl):3587. PMID: 27949683.
      Citations:    
    287. Salgia R, Sherman S, Hong DS, Ng CS, Frye J, Janisch L, Ratain MJ, Kurzrock R. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J Clin Oncol. 2008 May 20; 26(15_suppl):3522. PMID: 27949731.
      Citations:    
    288. McLeod HL, Owzar K, Kroetz D, Innocenti F, Das S, Friedman P, Giacomini K, Goldberg RM, Venook AP, Ratain MJ. Cellular transporter pharmacogenetics in metastatic colorectal cancer: Initial analysis of C80203. J Clin Oncol. 2008 May 20; 26(15_suppl):3513. PMID: 27949752.
      Citations:    
    289. Undevia SD, Janisch L, Schilsky RL, Loury D, Balasubramanian S, Mani C, Sirisawad M, Buggy JJ, Miller RA, Ratain MJ. Phase I study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-24781. J Clin Oncol. 2008 May 20; 26(15_suppl):14514. PMID: 27950776.
      Citations:    
    290. Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, Rich E, Borthakur G, Godley L, Verstovsek S, Artz A, Wierda W, Larson RA, Zhang Y, Cortes J, Ratain MJ, Giles FJ. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008 Aug; 26(4):331-8. PMID: 18425419; PMCID: PMC4905709.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    291. Rosner GL, Panetta JC, Innocenti F, Ratain MJ. Pharmacogenetic pathway analysis of irinotecan. Clin Pharmacol Ther. 2008 Sep; 84(3):393-402. PMID: 18418374; PMCID: PMC2759399.
      Citations: 20     Fields:    Translation:Humans
    292. Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL, Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA, Ratain MJ. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27. PMID: 18309947; PMCID: PMC5846189.
      Citations: 89     Fields:    Translation:Humans
    293. Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, Desai AA, Singleton PA, Sammani S, Sam L, Liu Y, Husain AN, Lang RM, Ratain MJ, Lussier YA, Garcia JG. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics. 2008 Apr 22; 33(2):278-91. PMID: 18303084; PMCID: PMC3616402.
      Citations: 49     Fields:    Translation:AnimalsCells
    294. Zhang W, Ratain MJ, Dolan ME. The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics. Bioinform Biol Insights. 2008; 2:15-23. PMID: 18392109; PMCID: PMC2288550.
      Citations: 26     
    295. Daugherty CK, Ratain MJ, Emanuel EJ, Farrell AT, Schilsky RL. Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol. 2008 Mar 10; 26(8):1371-8. PMID: 18227527.
      Citations: 15     Fields:    Translation:Humans
    296. Odenike OM, Larson RA, Gajria D, Dolan ME, Delaney SM, Karrison TG, Ratain MJ, Stock W. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9. PMID: 18217206; PMCID: PMC4283497.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    297. Ratain MJ, Glassman RH. Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6545-8. PMID: 18006752.
      Citations: 24     Fields:    Translation:Humans
    298. Liu W, Wu X, Zhang W, Montenegro RC, Fackenthal DL, Spitz JA, Huff LM, Innocenti F, Das S, Cook EH, Cox NJ, Bates SE, Ratain MJ. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6788-95. PMID: 18006781.
      Citations: 34     Fields:    Translation:HumansCells
    299. Ratain MJ, Humphrey RW, Gordon GB, Fyfe G, Adamson PC, Fleming TR, Stadler WM, Berry DA, Peck CC. Recommended changes to oncology clinical trial design: revolution or evolution? Eur J Cancer. 2008 Jan; 44(1):8-11. PMID: 17981025; PMCID: PMC2673461.
      Citations: 11     Fields:    Translation:Humans
    300. Chabner BA, Ratain MJ. Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control?". Clin Cancer Res. 2007 Nov 01; 13(21):6540. PMID: 17975169.
      Citations: 1     Fields:    Translation:Humans
    301. Maitland ML, Ratain MJ, Cox NJ. Interpreting P values in pharmacogenetic studies: a call for process and perspective. J Clin Oncol. 2007 Oct 10; 25(29):4513-5. PMID: 17925544.
      Citations: 14     Fields:    Translation:Humans
    302. Ratain MJ. The investigational drug steering committee. Clin Adv Hematol Oncol. 2007 Oct; 5(10):779-80. PMID: 17998895.
      Citations:    Fields:    Translation:Humans
    303. Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst. 2007 Oct 03; 99(19):1455-61. PMID: 17895472.
      Citations: 67     Fields:    Translation:Humans
    304. Liu W, Mirkov S, Desai AA, Chen P, Das S, Innocenti F, Ratain MJ, Ramírez J. Lack of association between common polymorphisms in UGT1A9 and gene expression and activity. Drug Metab Dispos. 2007 Dec; 35(12):2149-53. PMID: 17761781.
      Citations: 15     Fields:    Translation:HumansCells
    305. Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther. 2007 Oct; 82(4):381-8. PMID: 17728765.
      Citations: 97     Fields:    Translation:HumansAnimalsCells
    306. Gray SW, Hlubocky FJ, Ratain MJ, Daugherty CK. Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials. J Clin Oncol. 2007 Aug 10; 25(23):3488-94. PMID: 17687154.
      Citations: 9     Fields:    Translation:Humans
    307. Yoder Graber AL, Innocenti F, Ratain MJ, Ramírez J. UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers. Pharmacogenet Genomics. 2007 Aug; 17(8):619-27. PMID: 17622938.
      Citations: 8     Fields:    Translation:HumansCells
    308. Miller AA, Murry DJ, Owzar K, Hollis DR, Lewis LD, Kindler HL, Marshall JL, Villalona-Calero MA, Edelman MJ, Hohl RJ, Lichtman SM, Ratain MJ. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol. 2007 Jul 20; 25(21):3055-60. PMID: 17634483.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    309. Ratain MJ, Cohen EE. The value meal: how to save $1,700 per month or more on lapatinib. J Clin Oncol. 2007 Aug 10; 25(23):3397-8. PMID: 17635950.
      Citations: 23     Fields:    Translation:Humans
    310. Lewis LD, Miller AA, Rosner GL, Dowell JE, Valdivieso M, Relling MV, Egorin MJ, Bies RR, Hollis DR, Levine EG, Otterson GA, Millard F, Ratain MJ, Cancer and Leukemia Group B. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res. 2007 Jun 01; 13(11):3302-11. PMID: 17545536.
      Citations: 16     Fields:    Translation:Humans
    311. Altman RB, Benowitz N, Gurwitz D, Lunshof J, Relling M, Lamba J, Wieben E, Mooney S, Giacomini K, Weiss S, Johnson JA, McLeod H, Flockhart D, Weinshilboum R, Shuldiner AR, Roden D, Krauss RM, Ratain M. Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. Pharmacogenomics. 2007 May; 8(5):519. PMID: 17465717.
      Citations: 3     Fields:    
    312. Zhang W, Liu W, Innocenti F, Ratain MJ. Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms. PLoS One. 2007 Apr 25; 2(4):e396. PMID: 17460763; PMCID: PMC1851988.
      Citations: 13     Fields:    Translation:Humans
    313. Mirkov S, Zhang W, Chen P, Das S, Liu W, Ratain MJ, Innocenti F, Ramírez J. Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver. Pharmacogenomics J. 2008 Apr; 8(2):152-61. PMID: 17440429.
      Citations: 13     Fields:    Translation:Humans
    314. Michaelis LC, Ratain MJ. Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties. Clin Cancer Res. 2007 Apr 15; 13(8):2400-5. PMID: 17438099.
      Citations: 9     Fields:    Translation:Humans
    315. Ratain MJ. Personalized medicine: building the GPS to take us there. Clin Pharmacol Ther. 2007 Mar; 81(3):321-2. PMID: 17339859.
      Citations: 6     Fields:    Translation:Humans
    316. Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reus V, Roden DM, Schaefer CA, Shuldiner AR, Skaar T, Tantisira K, Tyndale RF, Wang L, Weinshilboum RM, Weiss ST, Zineh I, Pharmacogenetics Research Network. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007 Mar; 81(3):328-45. PMID: 17339863; PMCID: PMC5006950.
      Citations: 74     Fields:    Translation:HumansAnimals
    317. Parsad SD, Ratain MJ. Prescribing oral chemotherapy. BMJ. 2007 Feb 24; 334(7590):376. PMID: 17322214; PMCID: PMC1804145.
      Citations: 5     Fields:    Translation:Humans
    318. Yong WP, Desai AA, Innocenti F, Ramirez J, Shepard D, Kobayashi K, House L, Fleming GF, Vogelzang NJ, Schilsky RL, Ratain MJ. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2007 Nov; 60(6):811-9. PMID: 17308893.
      Citations: 11     Fields:    Translation:Humans
    319. Otterson GA, Villalona-Calero MA, Sharma S, Kris MG, Imondi A, Gerber M, White DA, Ratain MJ, Schiller JH, Sandler A, Kraut M, Mani S, Murren JR. Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res. 2007 Feb 15; 13(4):1246-52. PMID: 17317836.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    320. Hlubocky FJ, Ratain MJ, Wen M, Daugherty CK. Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making. J Clin Oncol. 2007 Feb 10; 25(5):548-54. PMID: 17290064.
      Citations: 35     Fields:    Translation:Humans
    321. Ratain MJ, Karrison TG. Testing the wrong hypothesis in phase II oncology trials: there is a better alternative. Clin Cancer Res. 2007 Feb 01; 13(3):781-2. PMID: 17289865.
      Citations: 6     Fields:    Translation:Humans
    322. Ramchandani RP, Wang Y, Booth BP, Ibrahim A, Johnson JR, Rahman A, Mehta M, Innocenti F, Ratain MJ, Gobburu JV. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol. 2007 Jan; 47(1):78-86. PMID: 17192505.
      Citations: 31     Fields:    Translation:Humans
    323. O'Donnell PH, Ratain MJ. Evaluating the activity of temsirolimus in neuroendocrine cancer. Br J Cancer. 2007 Jan 15; 96(1):177; author reply 178-9. PMID: 17164757; PMCID: PMC2360210.
      Citations: 4     Fields:    Translation:Humans
    324. Innocenti F, Ratain MJ. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics. 2006 Dec; 7(8):1211-21. PMID: 17184208.
      Citations: 23     Fields:    Translation:Humans
    325. Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, Krauss RM, McLeod HL, Ratain MJ, Relling MV, Ring HZ, Shuldiner AR, Weinshilboum RM, Weiss ST, Pharmacogenetics Research Network. Pharmacogenomics: challenges and opportunities. Ann Intern Med. 2006 Nov 21; 145(10):749-57. PMID: 17116919; PMCID: PMC5006954.
      Citations: 76     Fields:    Translation:Humans
    326. Mirkov S, Komoroski BJ, Graber AY, Ratain MJ, Strom SC, Innocenti F, Ramírez J. Effects of green tea compounds on irinotecan metabolism. Drug Metab Dispos. 2007 Feb; 35(2):228-33. PMID: 17108060.
      Citations: 6     Fields:    Translation:HumansCells
    327. Maitland ML, Ratain MJ. Terminal ballistics of kinase inhibitors: there are no magic bullets. Ann Intern Med. 2006 Nov 07; 145(9):702-3. PMID: 17088586.
      Citations: 14     Fields:    Translation:Humans
    328. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ, Ratain MJ. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006 Sep 04; 95(5):581-6. PMID: 16880785; PMCID: PMC2360687.
      Citations: 183     Fields:    Translation:HumansCTClinical Trials
    329. Lacouture ME, Desai A, Soltani K, Petronic-Rosic V, Laumann AE, Ratain MJ, Stadler WM. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol. 2006 Nov; 31(6):783-5. PMID: 16824050.
      Citations: 9     Fields:    Translation:Humans
    330. Maitland ML, Vasisht K, Ratain MJ. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci. 2006 Aug; 27(8):432-7. PMID: 16815558.
      Citations: 21     Fields:    Translation:Humans
    331. Yong WP, Innocenti F, Ratain MJ. The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol. 2006 Jul; 62(1):35-46. PMID: 16842377; PMCID: PMC1885075.
      Citations: 22     Fields:    Translation:Humans
    332. Ratain MJ, Miller AA, McLeod HL, Venook AP, Egorin MJ, Schilsky RL. The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3612s-6s. PMID: 16740794.
      Citations: 9     Fields:    Translation:Humans
    333. Maitland ML, DiRienzo A, Ratain MJ. Interpreting disparate responses to cancer therapy: the role of human population genetics. J Clin Oncol. 2006 May 10; 24(14):2151-7. PMID: 16682733.
      Citations: 12     Fields:    Translation:Humans
    334. Michaelis LC, Ratain MJ. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer. 2006 05; 6(5):409-14. PMID: 16633367.
      Citations: 79     Fields:    Translation:Humans
    335. Innocenti F, Vokes EE, Ratain MJ. Irinogenetics: what is the right star? J Clin Oncol. 2006 May 20; 24(15):2221-4. PMID: 16636339.
      Citations: 14     Fields:    Translation:Humans
    336. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jun 01; 24(16):2505-12. PMID: 16636341.
      Citations: 239     Fields:    Translation:HumansCTClinical Trials
    337. Lichtman SM, Hollis D, Miller AA, Rosner GL, Rhoades CA, Lester EP, Millard F, Byrd J, Cullinan SA, Rosen DM, Parise RA, Ratain MJ, Egorin MJ, Cancer and Leukemia Group B (CALGB 9762). Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol. 2006 Apr 20; 24(12):1846-51. PMID: 16567769.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    338. Ratain MJ. From bedside to bench to bedside to clinical practice: an odyssey with irinotecan. Clin Cancer Res. 2006 Mar 15; 12(6):1658-60. PMID: 16551845.
      Citations: 13     Fields:    Translation:Humans
    339. Komoroski BJ, Mirkov S, Graber AY, Fackenthal DL, Schuetz EG, Das S, Ratain MJ, Innocenti F, Strom SC, Ramírez J. Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes. Pharmacogenet Genomics. 2006 Feb; 16(2):79-86. PMID: 16424820.
      Citations: 7     Fields:    Translation:HumansCells
    340. Flockhart DA, Goldstein DB, Huang SM, Kroetz DL, Milos PM, Ratain MJ, Thummel K, Andersson T. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther. 2005 Dec; 78(6):559-81. PMID: 16338273.
      Citations: 16     Fields:    Translation:Humans
    341. Stadler WM, Michaelis LC, Ratain MJ. Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing? J Clin Oncol. 2005 Nov 01; 23(31):8124-5; author reply 8125-6. PMID: 16258115.
      Citations:    Fields:    Translation:Humans
    342. Yong WP, Ramirez J, Innocenti F, Ratain MJ. Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clin Cancer Res. 2005 Sep 15; 11(18):6699-704. PMID: 16166450.
      Citations: 20     Fields:    Translation:HumansCells
    343. Klein CE, Kastrissios H, Miller AA, Hollis D, Yu D, Rosner GL, Grinblatt DL, Larson RA, Ratain MJ. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol. 2006 Jan; 57(2):199-206. PMID: 16158312.
      Citations: 5     Fields:    Translation:Humans
    344. Ratain MJ. Phase II oncology trials: let's be positive. Clin Cancer Res. 2005 Aug 15; 11(16):5661-2. PMID: 16115898.
      Citations: 15     Fields:    Translation:Humans
    345. Stadler WM, Rosner G, Small E, Hollis D, Rini B, Zaentz SD, Mahoney J, Ratain MJ. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol. 2005 Jun 01; 23(16):3726-32. PMID: 15923569.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    346. Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer. 2005 Jun; 5(6):447-58. PMID: 15928675.
      Citations: 65     Fields:    Translation:HumansCells
    347. Michaelis LC, Ratain MJ. Analysis of phase II studies for the year 2002: Design, conclusions and impact factors of oncology vs. non-oncology trials. J Clin Oncol. 2005 Jun; 23(16_suppl):6059. PMID: 27945909.
      Citations:    
    348. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Gore M, Desai A, Patnaik A, Xiong HQ, Schwartz B, O'Dwyer P. Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol. 2005 Jun; 23(16_suppl):4544. PMID: 27946352.
      Citations:    
    349. Parker RS, Fisher JW, Florian JA, Venook AP, Ratain MJ, Egorin MJ. Development of a pharmacokinetically-guided gemcitabine (dFdC) dosing schedule to reduce potentially excessive plasma dFdC concentrations. J Clin Oncol. 2005 Jun; 23(16_suppl):2025. PMID: 27946851.
      Citations:    
    350. Desai AA, Kindler HL, Taber D, Agamah E, Mani S, Wade-Oliver K, Ratain MJ, Vokes EE. Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. Cancer Chemother Pharmacol. 2005 Oct; 56(4):421-6. PMID: 15895230.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    351. Innocenti F, Liu W, Chen P, Desai AA, Das S, Ratain MJ. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics. 2005 May; 15(5):295-301. PMID: 15864130.
      Citations: 24     Fields:    Translation:Humans
    352. French D, Wilkinson MR, Yang W, de Chaisemartin L, Cook EH, Das S, Ratain MJ, Evans WE, Downing JR, Pui CH, Relling MV. Global gene expression as a function of germline genetic variation. Hum Mol Genet. 2005 Jun 15; 14(12):1621-9. PMID: 15857854.
      Citations: 3     Fields:    Translation:HumansCells
    353. Desai AA, Schilsky RL, Young A, Janisch L, Stadler WM, Vogelzang NJ, Cadden S, Wright JA, Ratain MJ. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol. 2005 Jun; 16(6):958-65. PMID: 15824081.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    354. Liu W, Innocenti F, Ratain MJ. Linkage disequilibrium across the UGT1A locus should not be ignored in association studies of cancer susceptibility. Clin Cancer Res. 2005 Feb 01; 11(3):1348-9; author reply 1349. PMID: 15709208.
      Citations: 4     Fields:    Translation:Humans
    355. Desai AA, Ratain MJ. EGFR pharmacogenomics: the story continues to mutate and evolve. Am J Pharmacogenomics. 2005; 5(2):137-9. PMID: 15813677.
      Citations:    Fields:    Translation:Humans
    356. Liu W, Innocenti F, Wu MH, Desai AA, Dolan ME, Cook EH, Ratain MJ. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res. 2005 Jan 01; 65(1):46-53. PMID: 15665278.
      Citations: 67     Fields:    Translation:HumansCells
    357. Marshall JL, Kindler H, Deeken J, Bhargava P, Vogelzang NJ, Rizvi N, Luhtala T, Boylan S, Dordal M, Robertson P, Hawkins MJ, Ratain MJ. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs. 2005 Jan; 23(1):31-7. PMID: 15528978.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    358. Miller AA, Rosner GL, Egorin MJ, Hollis D, Lichtman SM, Ratain MJ. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res. 2004 Dec 15; 10(24):8325-31. PMID: 15623609.
      Citations: 8     Fields:    Translation:Humans
    359. Zimmerman TM, Harlin H, Odenike OM, Berk S, Sprague E, Karrison T, Stock W, Larson RA, Ratain MJ, Gajewski TF. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22. PMID: 15570084.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    360. Ahles TA, Herndon JE, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, Stadler W, Palchak D, Marshall ME, Wilding G, Petrylak D, Holland JC, Cancer and Leukemia Group B. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 2004 Nov 15; 101(10):2202-8. PMID: 15484217.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    361. Undevia SD, Kindler HL, Janisch L, Olson SC, Schilsky RL, Vogelzang NJ, Kimmel KA, Macek TA, Ratain MJ. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol. 2004 Nov; 15(11):1705-11. PMID: 15520075.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    362. Rudin CM, Marshall JL, Huang CH, Kindler HL, Zhang C, Kumar D, Gokhale PC, Steinberg J, Wanaski S, Kasid UN, Ratain MJ. Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res. 2004 Nov 01; 10(21):7244-51. PMID: 15534098.
      Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
    363. Innocenti F, Undevia SD, Mani S, Schilsky RL, Vogelzang NJ, Prado M, Ratain MJ, Ramírez J. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther. 2004 Nov; 76(5):490-502. PMID: 15536463.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    364. Undevia SD, Vogelzang NJ, Mauer AM, Janisch L, Mani S, Ratain MJ. Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs. 2004 Nov; 22(4):449-58. PMID: 15292715.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    365. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol. 2004 Nov 15; 22(22):4442-5. PMID: 15483011.
      Citations: 91     Fields:    Translation:Humans
    366. Odenike OM, Sobecks RM, Janisch L, Huo D, Zimmerman TM, Daugherty CK, Ratain MJ, Larson RA. A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. Cancer Chemother Pharmacol. 2004 Dec; 54(6):553-61. PMID: 15349753.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    367. Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ, Ramírez J. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep; 32(9):930-6. PMID: 15319333.
      Citations: 16     Fields:    Translation:HumansCells
    368. Desai AA, Innocenti F, Janisch L, DeMario M, Shepard D, Ramirez J, Fleming GF, Ratain MJ. A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2004 Nov; 54(5):377-84. PMID: 15235824.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    369. Helft PR, Schilsky RL, Hoke FJ, Williams D, Kindler HL, Sprague E, DeWitte M, Martino HK, Erickson J, Pandite L, Russo M, Lambert JM, Howard M, Ratain MJ. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 01; 10(13):4363-8. PMID: 15240523.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    370. Ryan CW, Vogelzang NJ, Vokes EE, Kindler HL, Undevia SD, Humerickhouse R, Wang Q, Carr RA, Ratain MJ, André AK. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res. 2004 Jul 01; 10(13):4406-11. PMID: 15240529.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    371. Dolan ME, Newbold KG, Nagasubramanian R, Wu X, Ratain MJ, Cook EH, Badner JA. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 2004 Jun 15; 64(12):4353-6. PMID: 15205351.
      Citations: 58     Fields:    Translation:HumansCells
    372. Innocenti F, Ratain MJ. "Irinogenetics" and UGT1A: from genotypes to haplotypes. Clin Pharmacol Ther. 2004 Jun; 75(6):495-500. PMID: 15179404.
      Citations: 8     Fields:    Translation:HumansAnimals
    373. Helft PR, Ratain MJ, Epstein RA, Siegler M. Inside information: Financial conflicts of interest for research subjects in early phase clinical trials. J Natl Cancer Inst. 2004 May 05; 96(9):656-61. PMID: 15126602.
      Citations:    Fields:    Translation:Humans
    374. Meyerhardt JA, Kwok A, Ratain MJ, McGovren JP, Fuchs CS. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2004 Apr 15; 22(8):1439-46. PMID: 15084617.
      Citations: 13     Fields:    Translation:Humans
    375. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Rudin CM, Vokes EE, Ratain MJ, Ramírez J. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004 Apr 15; 22(8):1382-8. PMID: 15007088.
      Citations: 273     Fields:    Translation:Humans
    376. Vogelzang NJ, Karrison T, Stadler WM, Garcia J, Cohn H, Kugler J, Troeger T, Giannone L, Arrieta R, Ratain MJ, Vokes EE. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer. 2004 Jan 01; 100(1):65-71. PMID: 14692025.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    377. Kimmick G, Ratain MJ, Berry D, Woolf S, Norton L, Muss HB, Cancer and Leukemia Group B (CALGB 9041). Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041). Invest New Drugs. 2004 Jan; 22(1):83-9. PMID: 14707498.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    378. Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol. 2003 Dec; 14(12):1783-90. PMID: 14630685.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    379. Desai AA, Innocenti F, Ratain MJ. Pharmacogenomics: road to anticancer therapeutics nirvana? Oncogene. 2003 Sep 29; 22(42):6621-8. PMID: 14528287.
      Citations: 10     Fields:    Translation:HumansCells
    380. Ratain MJ. Finding the right dose. Clin Adv Hematol Oncol. 2003 Sep; 1(9):517-8, 531. PMID: 16258442.
      Citations: 1     Fields:    Translation:Humans
    381. Desai AA, Innocenti F, Ratain MJ. UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics. 2003 Aug; 13(8):517-23. PMID: 12893990.
      Citations: 20     Fields:    Translation:Humans
    382. Murray PT, Ratain MJ. Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs. J Clin Oncol. 2003 Jul 15; 21(14):2633-5. PMID: 12860937.
      Citations: 4     Fields:    Translation:Humans
    383. Fleming GF, Schilsky RL, Schumm LP, Meyerson A, Hong AM, Vogelzang NJ, Ratain MJ. Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Ann Oncol. 2003 Jul; 14(7):1142-7. PMID: 12853359.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    384. Sawyer MB, Innocenti F, Das S, Cheng C, Pantle-Fisher FH, Wright C, Badner J, Pei D, Boyett JM, Cook E, Ratain MJ, Ramírez J. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther. 2003 Jun; 73(6):566-74. PMID: 12811366.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    385. Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer. 2003 May 15; 97(10):2480-6. PMID: 12733147.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    386. Innocenti F, Ratain MJ. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. Oncology (Williston Park). 2003 May; 17(5 Suppl 5):52-5. PMID: 12800608.
      Citations: 10     Fields:    Translation:HumansAnimals
    387. Sawyer MB, Ratain MJ, Bertucci D, Smith RP, Schilsky RL, Vogelzang NJ, Shulman K, Douglass EC, Fleming GF. Phase I study of an oral formulation of ZD9331 administered daily for 28 days. J Clin Oncol. 2003 May 01; 21(9):1859-65. PMID: 12721264.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    388. Liu W, Innocenti F, Chen P, Das S, Cook EH, Ratain MJ. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res. 2003 Mar; 9(3):1009-12. PMID: 12631599.
      Citations: 50     Fields:    Translation:HumansCells
    389. Masters GA, Brockstein BE, Mani S, Ratain MJ. Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors. Med Oncol. 2003; 20(1):7-12. PMID: 12665678.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    390. Innocenti F, Grimsley C, Das S, Cheng C, Kuttab-Boulos H, Ratain MJ, Di Rienzo A, Ramírez J. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics. 2002 Dec; 12(9):725-33. PMID: 12464801.
      Citations: 37     Fields:    Translation:HumansCells
    391. Fleming GF, Meropol NJ, Rosner GL, Hollis DR, Carson WE, Caligiuri M, Mortimer J, Tkaczuk K, Parihar R, Schilsky RL, Ratain MJ. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27. PMID: 12473581.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    392. Klein CE, Gupta E, Reid JM, Atherton PJ, Sloan JA, Pitot HC, Ratain MJ, Kastrissios H. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clin Pharmacol Ther. 2002 Dec; 72(6):638-47. PMID: 12496745.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    393. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol. 2002 Nov 15; 20(22):4478-84. PMID: 12431972.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    394. Schwartsmann G, Ratain MJ, Cragg GM, Wong JE, Saijo N, Parkinson DR, Fujiwara Y, Pazdur R, Newman DJ, Dagher R, Di Leone L. Anticancer drug discovery and development throughout the world. J Clin Oncol. 2002 Sep 15; 20(18 Suppl):47S-59S. PMID: 12235225.
      Citations: 27     Fields:    Translation:Humans
    395. Schellens JH, Ratain MJ. Endostatin: are the 2 years up yet? J Clin Oncol. 2002 Sep 15; 20(18):3758-60. PMID: 12228194.
      Citations: 2     Fields:    Translation:Humans
    396. Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol. 2002 Aug 15; 20(16):3369-75. PMID: 12177096.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    397. Karrison T, Ratain M. Troxacitabine in patients with refractory leukemia. J Clin Oncol. 2002 Aug 01; 20(15):3356; author reply 3356-7. PMID: 12149312.
      Citations:    Fields:    Translation:Humans
    398. Dolan ME, Posner M, Karrison T, Radosta J, Steinberg G, Bertucci D, Vujasin L, Ratain MJ. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res. 2002 Aug; 8(8):2519-23. PMID: 12171878.
      Citations: 5     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    399. Lathia C, Fleming GF, Meyer M, Ratain MJ, Whitfield L. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. Cancer Chemother Pharmacol. 2002 Aug; 50(2):121-6. PMID: 12172976.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    400. Ryan CW, Vokes EE, Vogelzang NJ, Janisch L, Kobayashi K, Ratain MJ. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer. Cancer Chemother Pharmacol. 2002 Jul; 50(1):1-5. PMID: 12111104.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    401. Innocenti F, Ratain MJ. Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res. 2002 May; 8(5):1314; author reply 1315-6. PMID: 12006555.
      Citations: 2     Fields:    Translation:HumansCells
    402. Iyer L, Journault K, Innocenti F, Ratain MJ, Guillemette C, Ramírez J, Bélanger P. In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharm Res. 2002 May; 19(5):588-94. PMID: 12069159.
      Citations: 10     Fields:    Translation:HumansCells
    403. Mani S, Rudin CM, Kunkel K, Holmlund JT, Geary RS, Kindler HL, Dorr FA, Ratain MJ. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res. 2002 Apr; 8(4):1042-8. PMID: 11948111.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    404. Ratain MJ. Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient. J Clin Oncol. 2002 Mar 15; 20(6):1434-5. PMID: 11896086.
      Citations: 8     Fields:    Translation:Humans
    405. Innocenti F, Ratain MJ. Update on pharmacogenetics in cancer chemotherapy. Eur J Cancer. 2002 Mar; 38(5):639-44. PMID: 11916544.
      Citations: 3     Fields:    Translation:Humans
    406. Shepard DR, Mani S, Kastrissios H, Learned-Coughlin S, Smith D, Ertel P, Magnum S, Janisch L, Fleming GF, Schilsky RL, Ratain MJ. Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. Cancer Chemother Pharmacol. 2002 May; 49(5):398-402. PMID: 11976834.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    407. Goh BC, Vokes EE, Joshi A, Ratain MJ. Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours. Br J Cancer. 2002 Feb 12; 86(4):534-9. PMID: 11870533; PMCID: PMC2375276.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    408. Iyer L, Shepard DR, Bingham CM, Hossfeld DK, Ratain MJ, Mayer U, Ramírez J. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother Pharmacol. 2002 Apr; 49(4):336-41. PMID: 11914914.
      Citations: 18     Fields:    Translation:Animals
    409. Schilsky RL, Bertucci D, Vogelzang NJ, Kindler HL, Ratain MJ. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002 Jan 15; 20(2):582-7. PMID: 11786589.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    410. Iyer L, Das S, Janisch L, Wen M, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ, Ramírez J. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2(1):43-7. PMID: 11990381.
      Citations: 178     Fields:    Translation:Humans
    411. Ratain MJ. Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"? J Clin Oncol. 2002 Jan 01; 20(1):7-8. PMID: 11773147.
      Citations: 18     Fields:    Translation:Humans
    412. Nagasubramanian R, Innocenti F, Ratain MJ. Pharmacogenetics in cancer treatment. Annu Rev Med. 2003; 54:437-52. PMID: 12525681.
      Citations: 18     Fields:    Translation:Humans
    413. Eng C, Mauer AM, Fleming GF, Bertucci D, Rotmensch J, Jacobs RH, Ratain MJ. Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors. Ann Oncol. 2001 Dec; 12(12):1743-7. PMID: 11843253.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    414. Mani S, Vogelzang NJ, Bertucci D, Stadler WM, Schilsky RL, Ratain MJ. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001 Sep 15; 92(6):1567-76. PMID: 11745236.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    415. Ratain MJ, Stadler WM. Clinical trial designs for cytostatic agents. J Clin Oncol. 2001 Jun 15; 19(12):3154-5. PMID: 11408513.
      Citations: 4     Fields:    Translation:Humans
    416. Innocenti F, Iyer L, Green MD, Ratain MJ, Ramírez J. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos. 2001 May; 29(5):686-92. PMID: 11302935.
      Citations: 32     Fields:    Translation:HumansCells
    417. Rudin CM, Holmlund J, Fleming GF, Mani S, Stadler WM, Schumm P, Monia BP, Johnston JF, Geary R, Yu RZ, Kwoh TJ, Dorr FA, Ratain MJ. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res. 2001 May; 7(5):1214-20. PMID: 11350886.
      Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
    418. Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs. 2001 May; 19(2):171-7. PMID: 11392451.
      Citations: 54     Fields:    Translation:HumansAnimals
    419. Ewesuedo RB, Iyer L, Das S, Koenig A, Mani S, Vogelzang NJ, Schilsky RL, Brenckman W, Ratain MJ. Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer. J Clin Oncol. 2001 Apr 01; 19(7):2084-90. PMID: 11283142.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    420. Innocenti F, Iyer L, Ratain MJ. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos. 2001 Apr; 29(4 Pt 2):596-600. PMID: 11259359.
      Citations: 20     Fields:    Translation:Humans
    421. Ratain MJ, Sheridan ME. Conflict-of-interest policies. N Engl J Med. 2001 Mar 29; 344(13):1018. PMID: 11280317.
      Citations:    Fields:    Translation:Humans
    422. Goh BC, Ratain MJ, Bertucci D, Smith R, Mani S, Vogelzang NJ, Schilsky RL, Hutchison M, Smith M, Averbuch S, Douglass E. Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J Clin Oncol. 2001 Mar 01; 19(5):1476-84. PMID: 11230494.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    423. Ratain MJ, Relling MV. Gazing into a crystal ball-cancer therapy in the post-genomic era. Nat Med. 2001 Mar; 7(3):283-5. PMID: 11231619.
      Citations: 3     Fields:    Translation:HumansAnimals
    424. Joshi AS, Pieniaszek HJ, Vokes EE, Vogelzang NJ, Davidson AF, Richards LE, Chai MF, Finizio M, Ratain MJ. Elimination pathways of [14C]losoxantrone in four cancer patients. Drug Metab Dispos. 2001 Feb; 29(2):96-9. PMID: 11159796.
      Citations: 1     Fields:    Translation:Humans
    425. Kastrissios H, Ratain MJ. Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis. Cancer Invest. 2001; 19(1):57-64. PMID: 11291557.
      Citations: 2     Fields:    Translation:Humans
    426. Innocenti F, Iyer L, Ratain MJ. Pharmacogenetics: a tool for individualizing antineoplastic therapy. Clin Pharmacokinet. 2000 Nov; 39(5):315-25. PMID: 11108431.
      Citations: 4     Fields:    Translation:Humans
    427. Benson AB, Olopade OI, Ratain MJ, Rademaker A, Mobarhan S, Stucky-Marshall L, French S, Dolan ME. Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients. Clin Cancer Res. 2000 Oct; 6(10):3870-7. PMID: 11051232.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    428. Ratain MJ. Insights into the pharmacokinetics and pharmacodynamics of irinotecan. Clin Cancer Res. 2000 Sep; 6(9):3393-4. PMID: 10999719.
      Citations: 3     Fields:    Translation:Humans
    429. Innocenti F, Stadler WM, Iyer L, Vokes EE, Ratain MJ, Ramírez J. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res. 2000 Sep; 6(9):3400-5. PMID: 10999721.
      Citations: 11     Fields:    Translation:Humans
    430. Schilsky RL, Dolan ME, Bertucci D, Ewesuedo RB, Vogelzang NJ, Mani S, Wilson LR, Ratain MJ. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res. 2000 Aug; 6(8):3025-31. PMID: 10955780.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    431. Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol. 2000 Jul; 18(14):2780-7. PMID: 10894879.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    432. Ryan CW, Fleming GF, Janisch L, Ratain MJ. A phase I study of liposomal doxorubicin (Doxil) with topotecan. Am J Clin Oncol. 2000 Jun; 23(3):297-300. PMID: 10857898.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    433. Daugherty CK, Banik DM, Janish L, Ratain MJ. Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB. 2000 May-Jun; 22(3):6-14. PMID: 11697385.
      Citations: 40     Fields:    Translation:Humans
    434. Stadler WM, Ratain MJ. Development of target-based antineoplastic agents. Invest New Drugs. 2000 Feb; 18(1):7-16. PMID: 10830137.
      Citations: 10     Fields:    Translation:Humans
    435. Goh BC, Fleming GF, Janisch L, Vogelzang NJ, Stadler WM, Ratain MJ. Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations. Cancer Chemother Pharmacol. 2000; 45(6):489-94. PMID: 10854137.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    436. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst. 1999 Aug 04; 91(15):1281-7. PMID: 10433616.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    437. Vokes EE, Goh BC, Bertucci D, Vogelzang NJ, Mani S, Ratain MJ. A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors. Cancer. 1999 Aug 01; 86(3):528-32. PMID: 10430263.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    438. Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ. Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies. Clin Cancer Res. 1999 Jun; 5(6):1325-30. PMID: 10389915.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    439. Iyer L, Hall D, Das S, Mortell MA, Kim S, Di Rienzo A, Ratain MJ, Ramírez J. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther. 1999 May; 65(5):576-82. PMID: 10340924.
      Citations: 84     Fields:    Translation:HumansCells
    440. Ratain MJ. Drug combinations: dangerous liaisons or great expectations? Ann Oncol. 1999 Apr; 10(4):375-6. PMID: 10370777.
      Citations: 1     Fields:    Translation:Humans
    441. Humerickhouse RA, Dolan ME, Haraf DJ, Brockstein B, Stenson K, Kies M, Sulzen L, Ratain MJ, Vokes EE. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res. 1999 Feb; 5(2):291-8. PMID: 10037177.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    442. Iyer L, Ratain MJ. 5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Invest. 1999; 17(7):494-506. PMID: 10518194.
      Citations: 11     Fields:    Translation:HumansAnimals
    443. DeMario MD, Ratain MJ, Vogelzang NJ, Mani S, Vokes EE, Fleming GF, Melton K, Johnson S, Benner S, Lebwohl D. A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days. Cancer Chemother Pharmacol. 1999; 43(5):385-8. PMID: 10100593.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    444. House LK, Ratain MJ, Ramírez J. Simultaneous determination of 5-fluorouracil and uracil by high-performance liquid chromatography using four serial columns. J Chromatogr B Biomed Sci Appl. 1998 Dec 11; 720(1-2):245-50. PMID: 9892089.
      Citations: 1     Fields:    Translation:Humans
    445. Lilenbaum RC, Miller AA, Batist G, Bernard S, Hollis DR, Rosner GL, Egorin MJ, Schilsky RL, Ratain MJ. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study. J Clin Oncol. 1998 Oct; 16(10):3302-9. PMID: 9779705.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    446. Vokes EE, Ansari RH, Masters GA, Hoffman PC, Klepsch A, Ratain MJ, Sciortino DF, Lad TE, Krauss S, Fishkin PA, Golomb HM. A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer. Ann Oncol. 1998 Oct; 9(10):1085-90. PMID: 9834820.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    447. Iyer L, Ratain MJ. Pharmacogenetics and cancer chemotherapy. Eur J Cancer. 1998 Sep; 34(10):1493-9. PMID: 9893619.
      Citations: 15     Fields:    Translation:Humans
    448. Ratain MJ. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol. 1998 Jul; 16(7):2297-8. PMID: 9667242.
      Citations: 38     Fields:    Translation:Humans
    449. Daugherty CK, Ratain MJ, Minami H, Banik DM, Vogelzang NJ, Stadler WM, Siegler M. Study of cohort-specific consent and patient control in phase I cancer trials. J Clin Oncol. 1998 Jul; 16(7):2305-12. PMID: 9667244.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    450. DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol. 1998 Jul; 16(7):2557-67. PMID: 9667278.
      Citations: 56     Fields:    Translation:Humans
    451. Saleh MN, LeMaistre CF, Kuzel TM, Foss F, Platanias LC, Schwartz G, Ratain M, Rook A, Freytes CO, Craig F, Reuben J, Sams MW, Nichols JC. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol. 1998 Jul; 39(1):63-73. PMID: 9674399.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    452. Fleming GF, Kugler JW, Hoffman PC, Ansari R, Bitran JD, Klepsch A, Malone D, Fasanmade AA, Ratain MJ, Vokes EE. Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer. J Clin Oncol. 1998 Jun; 16(6):2032-7. PMID: 9626200.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    453. Dolan ME, Roy SK, Fasanmade AA, Paras PR, Schilsky RL, Ratain MJ. O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol. 1998 May; 16(5):1803-10. PMID: 9586894.
      Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
    454. Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM, Schilsky RL. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol. 1998 May; 16(5):1811-9. PMID: 9586895.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    455. Rini BI, Stadler WM, Spielberger RT, Ratain MJ, Vogelzang NJ. Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial. Cancer. 1998 Apr 01; 82(7):1352-8. PMID: 9529028.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    456. Schilsky RL, Hohneker J, Ratain MJ, Janisch L, Smetzer L, Lucas VS, Khor SP, Diasio R, Von Hoff DD, Burris HA. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol. 1998 Apr; 16(4):1450-7. PMID: 9552051.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    457. Vogelzang NJ, Mani S, Schilsky RL, Ansari RH, Taber D, Rhinehart SN, Garcia JC, Meyer SC, Mick R, Brockstein BE, Stadler WM, Ratain MJ, Vokes EE. Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Clin Cancer Res. 1998 Apr; 4(4):929-34. PMID: 9563886.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    458. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998 Feb 15; 101(4):847-54. PMID: 9466980; PMCID: PMC508633.
      Citations: 165     Fields:    Translation:HumansAnimalsCells
    459. Brockstein B, Haraf DJ, Stenson K, Fasanmade A, Stupp R, Glisson B, Lippman SM, Ratain MJ, Sulzen L, Klepsch A, Weichselbaum RR, Vokes EE. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol. 1998 Feb; 16(2):735-44. PMID: 9469365.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    460. LeMaistre CF, Saleh MN, Kuzel TM, Foss F, Platanias LC, Schwartz G, Ratain M, Rook A, Freytes CO, Craig F, Reuben J, Nichols JC. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood. 1998 Jan 15; 91(2):399-405. PMID: 9427692.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    461. Mani S, Iyer L, Janisch L, Wang X, Fleming GF, Schilsky RL, Ratain MJ. Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol. 1998; 42(1):84-7. PMID: 9619763.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    462. Iyer L, Ratain MJ. Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol. 1998; 42 Suppl:S31-43. PMID: 9750027.
      Citations: 13     Fields:    Translation:HumansAnimals
    463. DeMario MD, Ratain MJ. Rationale for phase I study of UFT plus leucovorin and oral JM-216. Oncology (Williston Park). 1997 Sep; 11(9 Suppl 10):26-9. PMID: 9348563.
      Citations:    Fields:    Translation:Humans
    464. Ratain MJ, Skoog LA, O'Brien SM, Cooper N, Schilsky RL, Vogelzang NJ, Gerber M, Narang PK, Nicol SJ. Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule. Ann Oncol. 1997 Aug; 8(8):807-9. PMID: 9332692.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    465. Boddy AV, Ratain MJ. Pharmacogenetics in cancer etiology and chemotherapy. Clin Cancer Res. 1997 Jul; 3(7):1025-30. PMID: 9815780.
      Citations: 2     Fields:    Translation:HumansAnimals
    466. Daugherty CK, Siegler M, Ratain MJ, Zimmer G. Learning from our patients: one participant's impact on clinical trial research and informed consent. Ann Intern Med. 1997 Jun 01; 126(11):892-7. PMID: 9163291.
      Citations: 3     Fields:    Translation:Humans
    467. Miller AA, Rosner GL, Ratain MJ, Hollis DR, Green MR, Schilsky RL. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062). Clin Cancer Res. 1997 May; 3(5):719-25. PMID: 9815741.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    468. Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE, Ratain MJ. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol. 1997 Apr; 15(4):1502-10. PMID: 9193346.
      Citations: 27     Fields:    Translation:Humans
    469. Mani S, Ratain MJ. New phase I trial methodology. Semin Oncol. 1997 Apr; 24(2):253-61. PMID: 9129693.
      Citations: 1     Fields:    Translation:Humans
    470. Johnston PG, Mick R, Recant W, Behan KA, Dolan ME, Ratain MJ, Beckmann E, Weichselbaum RR, Allegra CJ, Vokes EE. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst. 1997 Feb 19; 89(4):308-13. PMID: 9048835.
      Citations: 14     Fields:    Translation:Humans
    471. Fleming GF, O'Brien SM, Hoffman PC, Vokes EE, Vogelzang NJ, Schilsky RL, Waggoner SE, Ratain MJ. Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin. Cancer Chemother Pharmacol. 1997; 39(3):227-32. PMID: 8996525.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    472. Gupta E, Wang X, Ramirez J, Ratain MJ. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol. 1997; 39(5):440-4. PMID: 9054958.
      Citations: 18     Fields:    Translation:Animals
    473. Ogan K, Ratain MJ, Ramírez J. Determination of vinca alkaloids in human plasma by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. Cancer Chemother Pharmacol. 1997; 39(4):286-90. PMID: 9025768.
      Citations: 2     Fields:    Translation:Humans
    474. Nichols J, Foss F, Kuzel TM, LeMaistre CF, Platanias L, Ratain MJ, Rook A, Saleh M, Schwartz G. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer. 1997 Jan; 33 Suppl 1:S34-6. PMID: 9166099.